<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        9-665-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        REVOLADE 50MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ELTROMBOPAG OLAMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4939.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Siegfried Barbera S.L" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Siegfried Barbera S.L
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Revolade contains the active ingredient eltrombopag, which belongs to a group of medicines called thrombopoietin receptor agonists<em>. </em>Revolade stimulates the bone marrow (part of the bone that makes blood cells) to produce more platelets. It is used to help increase the number of platelets in your blood. Platelets are blood cells that help to reduce or prevent bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revolade is used to treat a bleeding disorder called immune (Primary) thrombocytopenia (ITP) in patients aged 1 year and above who have already taken other medicines (corticosteroids or immunoglobulins), which have not worked.</p><p>&nbsp;</p><p>ITP is caused by a low blood platelet count (thrombocytopenia). People with ITP have an increased risk of bleeding. Symptoms patients with ITP may notice include petechiae (pinpoint- sized flat round red spots under the skin), bruising, nosebleeds, bleeding gums and not being able to control bleeding if they are cut or injured.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revolade can also be used to treat low platelet count (thrombocytopenia) in adults with hepatitis C virus (HCV) infections, if they have had problems with side effects while on interferon treatment. Many people with hepatitis C have low platelet counts, not only as a result of the disease, but also due to some of the antiviral medicines that are used to treat it. Taking Revolade may make it easier for you to complete a full course of antiviral medicine (peginterferon and ribavirin).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Revolade may also be used to treat adult patients with low blood counts caused by severe aplastic anaemia (SAA). SAA is a disease in which the bone marrow is damaged, causing a deficiency of the red blood cells (anaemia), white blood cells (leukopenia) and platelets (thrombocytopenia).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; For the first-line treatment of acquired severe aplastic anaemia (SAA) in combination with standard immunosuppressive therapy in adult and paediatric patients aged 2 years and over who are unsuitable for haematopoietic stem cell transplantation at the time of diagnosis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. </strong><strong>Do not take Revolade</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic </strong>to eltrombopag or any of the other ingredients of this medicine (listed in section 6 under <strong><em>&lsquo;What Revolade contains&rsquo;</em></strong>).</p><p>&nbsp;</p><p><strong>Check with your doctor </strong>if you think this applies to you.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take special care with Revolade</strong></p><p>If any of the following applies to you/your child, talk to your doctor or pharmacist before taking Revolade:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>liver problems</strong>. People who have low platelet counts as well as advanced chronic (long-term) liver disease are more at risk of side effects, including life-threatening liver damage and blood clots. If your doctor considers that the benefits of taking Revolade outweigh the risks, you will be closely monitored during treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have kidney problems as Revolade should be used with caution.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are at risk of <strong>blood clots </strong>in your veins or arteries, or you know that blood clots are common in your family.</p><p>&nbsp;</p><p>You may be at <strong>higher risk of blood clots</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp; as you get older</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have had to stay in bed for a long time</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have cancer</p><p>&middot;&nbsp;&nbsp;&nbsp; if you are taking the contraceptive birth control pill or hormone replacement therapy</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have recently had surgery or received a physical injury</p><p>&middot;&nbsp;&nbsp;&nbsp; if you are very overweight (obese)</p><p>&middot;&nbsp;&nbsp;&nbsp; if you are a smoker</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have advanced chronic liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp; If any of these apply to you, <strong>tell your doctor </strong>before starting treatment. You should not take Revolade unless your doctor considers that the expected benefits outweigh the risk of blood clots.</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have <strong>cataracts </strong>(the lens of the eye getting cloudy)</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have another <strong>blood condition</strong>, such as myelodysplastic syndrome (MDS). Your doctor will carry out tests to check that you do not have this blood condition before you start Revolade. If you have MDS and take Revolade, your MDS may get worse.</p><p>Tell your doctor if any of these apply to you.</p><p>&nbsp;</p><p><strong>Eye examinations</strong></p><p>Your doctor will recommend that you are checked for cataracts. If you do not have routine eye-tests your doctor should arrange regular testing. You may also be checked for the occurrence of any bleeding in or around your retina (the light-sensitive layer of cells at the back of the eye).</p><p>&nbsp;</p><p><strong>You will need regular tests</strong></p><p>Before you start taking Revolade, your doctor will carry out blood tests to check your blood cells, including platelets. These tests will be repeated at intervals while you are taking it.</p><p>&nbsp;</p><p><strong>Blood tests for liver function</strong></p><p>Revolade can cause blood test results that may be signs of liver damage - an increase of some liver enzymes, especially bilirubin and alanine / aspartate transaminases. If you are taking interferon-based treatments together with Revolade to treat low platelet count due to hepatitis C, some liver problems can get worse.</p><p>&nbsp;</p><p>You will have blood tests to check your liver function before you start taking Revolade and at intervals while you are taking it. You may need to stop taking Revolade if the amount of these substances increases too much, or if you get other signs of liver damage.</p><p><strong>Read the information &lsquo;<em>Liver problems</em>&rsquo; in section 4 of this leaflet.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Blood tests for platelet count</strong></p><p>If you stop taking Revolade, your blood platelet count is likely to become low again within several</p><p>&nbsp;</p><p>days. The platelet count will be monitored, and your doctor will discuss appropriate precautions with you.</p><p>&nbsp;</p><p>A very high blood platelet count may increase the risk of blood clotting. However, blood clots can also form with normal or even low platelet counts. Your doctor will adjust your dose of Revolade to ensure that your platelet count does not become too high.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_8" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Image" style='width:19.5pt;height:18.75pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.jpg"
  o:title="Image"/>
</v:shape><![endif]--><img width="26" height="25" alt="Image" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" />&nbsp;<strong>Get medical help immediately </strong>if you have any of these signs of a <strong>blood clot</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>swelling</strong>, <strong>pain </strong>or tenderness in <strong>one leg</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>sudden shortness of breath </strong>especially together with sharp pain in the chest or rapid breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal (stomach) pain, enlarged abdomen, blood in your stools</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have cirrhosis of the liver, there is a risk of a blood clot forming in an artery leading to the liver (portal vein thrombosis). Serious complications from some types of blood clots include blood clots in the lungs, heart attacks or strokes. Your doctor will check your platelet count and adjust your dose or stop Revolade if the platelet count is too high.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience signs of impaired liver function such as yellowing of the skin or the conjunctiva of the eyes (jaundice), unusual dark color of the urine, unusual tiredness, pain in the right upper abdomen. Revolade could damage your liver and even cause life-threatening illnesses.</p><p>&nbsp;</p><p><strong>Monitoring during your treatment with Revolade</strong></p><p><strong>&nbsp;</strong></p><p><strong>Tests to check your bone marrow</strong></p><p>In people who have problems with their bone marrow, medicines like Revolade could make the problems worse. Signs of bone marrow changes may show up as abnormal results in your blood tests. Your doctor may also carry out tests to directly check your bone marrow during treatment with Revolade.</p><p>&nbsp;</p><p><strong>Checks for digestive bleeding</strong></p><p>If you are taking interferon-based treatments together with Revolade you will be monitored for any signs of bleeding in your stomach or intestine after you stop taking Revolade.</p><p>&nbsp;</p><p><strong>Heart monitoring</strong></p><p>Your doctor may consider it necessary to monitor your heart during treatment with Revolade and carry out an electrocardiogram (ECG) test.</p><p>&nbsp;</p><p><strong>Older people (65 years and older)</strong></p><p>There are limited data available on the use of Revolade in patients 65 years of age and older. Revolade should be used with caution in patients 65 years of age and older.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Revolade is not recommended for children aged under 1 year who have ITP. It is also not recommended for people under 18 years with low platelet counts due to hepatitis C or severe aplastic anaemia.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Taking other medicines, herbal or dietary supplements</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Some everyday medicines interact with Revolade </strong>&ndash; including prescription and non-prescription</p><p>medicines and minerals. These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antacid medicines to treat <strong>indigestion</strong>, <strong>heartburn </strong>or <strong>stomach ulcers </strong>(see also &lsquo;<strong><em>When to take it</em></strong>&rsquo; in section 3)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines called statins, to <strong>lower cholesterol</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines to treat <strong>HIV infection</strong>, such as lopinavir and/or ritonavir</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin used in the context of <strong>transplantations </strong>or <strong>immune diseases</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; minerals such as iron, calcium, magnesium, aluminium, selenium and zinc which may be found in <strong>vitamin and mineral supplements </strong>(see also <strong><em>&lsquo;When to take it&rsquo; </em></strong>in section 3)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines such as methotrexate and topotecan, to treat <strong>cancer</strong></p><p><strong>Talk to your doctor </strong>if you take any of these. Some of them are not to be taken with Revolade, or the dose may need adjusting, or you may need to alter the timing of when you take them. Your doctor will review the medicines you are taking and suggest suitable replacements if necessary.</p><p>&nbsp;</p><p>If you are also taking medicines to prevent blood clots there is a greater risk of bleeding. Your doctor will discuss this with you.</p><p>&nbsp;</p><p>If you are taking <strong>corticosteroids, danazol, </strong>and/or <strong>azathioprine </strong>you may need to take a lower dose or to stop taking them while you are taking Revolade.</p><p>&nbsp;</p><p><strong>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking Revolade with food and drink</strong></p><p>Do not take Revolade with dairy foods or drinks as the calcium in dairy products affects the absorption of the medicine. For more information, see &lsquo;<strong><em>When to take it&rsquo; </em></strong>in section 3.</p><p>&nbsp;</p><p><strong>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy and breast-feeding</strong></p><p><strong>Don&rsquo;t use Revolade if you are pregnant </strong>unless your doctor specifically recommends it. The effect of Revolade during pregnancy is not known.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor if you are pregnant, </strong>think you may be pregnant, or are planning to have a baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Use a reliable method of contraception </strong>while you&rsquo;re taking Revolade, to prevent pregnancy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you do become pregnant during treatment </strong>with Revolade, tell your doctor.</p><p>&nbsp;</p><p><strong>Don&rsquo;t breast-feed while you are taking Revolade</strong>. It is not known whether Revolade passes into breast-milk.</p><p><strong>If you are breast-feeding </strong>or planning to breast-feed, tell your doctor</p><p>&nbsp;</p><p><strong>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Driving and using machines</strong></p><p><strong>Revolade can make you dizzy </strong>and have other side effects that make you less alert.</p><p><strong>Don&rsquo;t drive or use machines </strong>unless you are sure you&rsquo;re not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Do not change the dose or schedule for taking Revolade unless your doctor or pharmacist advises you to. While you are taking Revolade, you will be under the care of a doctor with specialist experience in treating your condition.</p><p>&nbsp;</p><p><strong>How much to take for ITP</strong></p><p><strong>Adults </strong>and <strong>children </strong>(6 to 17 years) &ndash; the usual starting dose for ITP is <strong>one 50 mg tablet </strong>of Revolade a day. If you are of East Asian origin (Chinese, Japanese, Taiwanese, Thai or Korean) you may need to start at a <strong>lower dose of 25 mg.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Children </strong>(1 to 5 years) &mdash; the usual starting dose for ITP is <strong>one 25 mg tablet </strong>of Revolade a day.</p><p>&nbsp;</p><p><strong>For hepatitis C</strong></p><p><strong>Adults - </strong>the usual starting dose for hepatitis C is <strong>one 25 mg tablet </strong>of Revolade a day. If you are of East Asian origin (Chinese, Japanese, Taiwanese, Thai or Korean) you will start on the <strong>same 25 mg dose.</strong></p><p><strong>&nbsp;</strong></p><p><strong>For SAA</strong></p><p><strong>Adults - </strong>the usual starting dose for SAA is <strong>one 50 mg tablet </strong>of Revolade a day. If you are of East Asian origin (Chinese, Japanese, Taiwanese, Thai or Korean) you may need to start at a <strong>lower dose of 25 mg.</strong></p><p><strong>&nbsp;</strong></p><p>Revolade may take 1 to 2 weeks to work. Based on your response to Revolade your doctor may recommend that your daily dose is changed.</p><p>&nbsp;</p><p><strong>How to take the tablets</strong></p><p>Swallow the tablet whole, with some water.</p><p>&nbsp;</p><p><strong>When to take it</strong></p><p>Make sure that <strong>you don&rsquo;t </strong>consume any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>dairy foods </strong>such as cheese, butter, yoghurt or ice cream</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>milk or milk shakes, </strong>drinks containing milk, yoghurt or cream</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>antacids, </strong>a type of medicine for <strong>indigestion and heartburn</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; some <strong>mineral and vitamin supplements </strong>including iron, calcium, magnesium, aluminium, selenium and zinc</p><p>&nbsp;</p><p>o in the <strong>4 hours before </strong>you take Revolade</p><p>o and the <strong>2 hours after </strong>you take Revolade</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; If you do, the medicine will not be properly absorbed into your body.</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_7" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Image" style='width:168pt;height:129pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.jpg"
  o:title="Image"/>
</v:shape><![endif]--><img width="224" height="172" alt="Image" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /></p><p><strong>&nbsp;</strong></p><p><strong>For more advice about suitable foods and drinks, talk to your doctor.</strong></p><p><strong>&nbsp;</strong></p><p><strong>If you take more Revolade than you should</strong></p><p><strong>Contact a doctor or pharmacist immediately</strong>. If possible show them the pack, or this leaflet.</p><p>You will be monitored for any signs or symptoms of side effects and given appropriate treatment immediately.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you forget to take Revolade</strong></p><p>Take the next dose at the usual time. Do not take more than one dose of Revolade in one day.</p><p>&nbsp;</p><p><strong>C . If you stop taking Revolade</strong></p><p>Don&rsquo;t stop taking Revolade without talking to your doctor. If your doctor advises you to stop treatment, your platelet count will then be checked each week for four weeks. See also <em>&lsquo;<strong>Bleeding or bruising after you stop treatment</strong></em>&rsquo; in section 4.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>*The Powder for oral solution supporting the age group from 1 to 5 years old is not registered</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Symptoms needing attention: see a doctor</strong></p><p>People taking Revolade for either ITP or low blood platelet counts due to hepatitis C could develop signs of potentially serious side effects. <strong>It is important to tell a doctor if you develop these symptoms</strong>.</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people: </strong></p><p><strong>Higher risk of blood clots</strong></p><p>Certain people may have a higher risk of blood clots, and medicines like Revolade could make this problem worse. The sudden blocking of a blood vessel by a blood clot is an uncommon side effect and may affect up to 1 in 100 people.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_10" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Image" style='width:18.75pt;height:18.75pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.jpg"
  o:title="Image"/>
</v:shape><![endif]--><img width="25" height="25" alt="Image" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /><strong>Get medical help immediately if you develop signs and symptoms of a blood clot, such as</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>swelling, pain, heat, redness, </strong>or tenderness in <strong>one leg</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>sudden shortness of breath</strong>, especially together with sharp pain in the chest or rapid breathing</p><p>&middot;&nbsp;&nbsp;&nbsp; abdominal (stomach) pain, enlarged abdomen, blood in your stools.</p><p>&nbsp;</p><p><strong>Uncommon: may affect up to 1 in 100 people:</strong></p><p><strong>Liver problems</strong></p><p>Revolade can cause changes that show up in blood tests and may be signs of liver damage. Liver problems (increased enzymes showing up in blood tests) are common and may affect up to 1 in</p><p>10 people. Other liver problems (bile not flowing properly) are uncommon and may affect up to 1 in</p><p>100 people.</p><p>If you have either of these signs of liver problems:</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>yellowing </strong>of the skin or the whites of the eyes (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp; unusually <strong>dark-coloured urine</strong></p><p>&nbsp;</p><p><strong>Kidney failure: </strong>includes severely reduced urine production</p><p>&nbsp;</p><p><strong>Tell your doctor immediately</strong>.</p><p>&nbsp;</p><p><strong>Bleeding or bruising after you stop treatment</strong></p><p>Within two weeks of stopping Revolade, your blood platelet count will usually drop back down to what it was before starting Revolade. The lower platelet count may increase the risk of bleeding or bruising. Your doctor will check your platelet count for at least 4 weeks after you stop taking Revolade.</p><p>&egrave;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor </strong>if you have any bleeding or bruising after stopping Revolade.</p><p>&nbsp;</p><p>Some people have <strong>bleeding in the digestive system </strong>after they stop taking peginterferon, ribavirin, and Revolade. Symptoms include:</p><p>&middot;black tarry stools (discoloured bowel movements are a uncommon side effect that may affect up to 1 in 100 people)</p><p>&middot;blood in your stools</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting blood or something that looks like coffee grounds</p><p>&nbsp;</p><p>&egrave;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor </strong>immediately if you have any of these symptoms.</p><p>&nbsp;</p><p><strong>The following side effects have been reported to be associated with treatment with Revolade in adult patients with ITP:</strong></p><p><strong>Very common side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; These may affect <strong>more than 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp; sore throat, cough and runny nose</p><p>&middot;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp; fatigue</p><p>&middot;&nbsp;&nbsp;&nbsp; infection in the nose, sinuses, throat and upper airways, common cold (upper respiratory tract infection)</p><p>&nbsp;</p><p><strong>Very common side effects that may show up in blood tests:</strong></p><p>increased of liver enzymes (alanine aminotransferase (ALT))</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp; muscle pain, muscle spasm, muscle weakness</p><p>&middot;&nbsp;&nbsp;&nbsp; bone pain</p><p>&middot;&nbsp;&nbsp;&nbsp; sore throat and discomfort when swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp; eye problems including (abnormal eye test, dry eye, eye pain and blurred vision, conjunctival bleeding)</p><p>&middot;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp; flu-like symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp; chest pain when breathing (pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp; swelling (edema)</p><p>&middot;&nbsp;&nbsp;&nbsp; bleeding gum</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling of tingling, prickling or numbness, commonly called &ldquo;pins and needles&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling drowsy</p><p>&middot;&nbsp;&nbsp;&nbsp; ear pain</p><p>&middot;&nbsp;&nbsp;&nbsp; pain, swelling and tenderness in one of your legs (usually the calf) with warm skin in the affected area (signs of a blood clot in a deep vein)</p><p>&middot;&nbsp;&nbsp;&nbsp; localised swelling filled with blood from a break in a blood vessel (haematoma)</p><p>&middot;&nbsp;&nbsp;&nbsp; mouth problems including dry mouth, sore mouth, sensitive tongue, bleeding gums, mouth ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp; toothache</p><p>&middot;&nbsp;&nbsp;&nbsp; stomach pain and tenderness</p><p>&middot;&nbsp;&nbsp;&nbsp; liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp; skin changes including excessive sweating, itching bumpy rash, red spots, changes in appearance of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp; foamy, frothy or bubbly-looking urine (signs of protein in urine)</p><p>&middot;&nbsp;&nbsp;&nbsp; generally feeling unwell, high temperature, feeling hot</p><p>&middot;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp; problems sleeping, depression</p><p>&middot;&nbsp;&nbsp;&nbsp; migraine</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased vision</p><p>&middot;&nbsp;&nbsp;&nbsp; spinning sensation (vertigo)</p><p>&middot;&nbsp;&nbsp;&nbsp; Digestive wind/gas</p><p>&middot;&nbsp;&nbsp;&nbsp; Hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p><strong>Common side effects that may show up in blood test:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; decreased number of red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased number of platelets (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased number of white blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased haemaglobin level</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased number of eosinophils</p><p>&middot;&nbsp;&nbsp;&nbsp; increased number of white blood cells (leukocytosis)</p><p>&middot;&nbsp;&nbsp;&nbsp; increased levels of uric acid</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased levels of potassium</p><p>&middot;&nbsp;&nbsp;&nbsp; increased levels of creatinine</p><p>&middot;&nbsp;&nbsp;&nbsp; increased levels of alkaline phosphatase</p><p>&middot;&nbsp;&nbsp;&nbsp; increase of liver enzymes (aspartate aminotransferase (AST))</p><p>&middot;&nbsp;&nbsp;&nbsp; increase in bilirubin (a substance produced by the liver)</p><p>&middot;&nbsp;&nbsp;&nbsp; increased levels of some proteins</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong></p><p>These may affect <strong>up to 1 in 100 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp; interruption of blood supply to part of the heart</p><p>&middot;&nbsp;&nbsp;&nbsp; sudden shortness of breath, especially when accompanied with sharp pain in the chest and /or rapid breathing, which could be signs of a blood clot in the lungs (see <em>&lsquo;<strong>Higher risk of blood clots</strong>&rsquo; </em>earlier in section 2)</p><p>&middot;&nbsp;&nbsp;&nbsp; the loss of function of part of the lung caused by a blockage in the lung artery</p><p>&middot;&nbsp;&nbsp;&nbsp; liver problems, including yellowing of the eyes and skin (see &lsquo;<strong><em>Liver problems&rsquo; </em></strong>earlier in section 2)</p><p>&middot;&nbsp;&nbsp;&nbsp; the loss of function of part of the lung caused by a blockage in the lung artery including yellowing of the eyes and skin (see &lsquo;Liver problems&rsquo; earlier in section 2)</p><p>&middot;&nbsp;&nbsp;&nbsp; liver injury due to medication</p><p>&middot;&nbsp;&nbsp;&nbsp; heart beating faster, irregular heartbeat, bluish discolouration of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp; disturbances of heart rhythm (QT prolongation)</p><p>&middot;&nbsp;&nbsp;&nbsp; blood clot</p><p>&middot;&nbsp;&nbsp;&nbsp; painful swollen joints caused by uric acid (gout)</p><p>&middot;&nbsp;&nbsp;&nbsp; lack of interest, mood changes</p><p>&middot;&nbsp;&nbsp;&nbsp; problems with balance, speech and nerve function, shaking</p><p>&middot;&nbsp;&nbsp;&nbsp; eye problems including increased production of tears, cloudy lens in the eye (cataract), bleeding of the retina</p><p>&middot;&nbsp;&nbsp;&nbsp; problems with the nose, throat and sinuses, breathing problems when sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp; digestive system problems including frequent bowel movements, food poisoning, blood in stool</p><p>&middot;&nbsp;&nbsp;&nbsp; rectal bleeding, blood in your stool, abdominal bloating, constipation</p><p>&middot;&nbsp;&nbsp;&nbsp; mouth problems, including dry or sore mouth, sensitive tongue, bleeding gums</p><p>&middot;&nbsp;&nbsp;&nbsp; sunburn</p><p>&middot;&nbsp;&nbsp;&nbsp; redness or swelling around, a wound bleeding around a catheter (if present) into the skin sensation of a foreign body</p><p>&middot;&nbsp;&nbsp;&nbsp; kidney problems including inflammation of the kidney, excessive urination at night, kidney failure, white cells in urine</p><p>&middot;&nbsp;&nbsp;&nbsp; cold sweat</p><p>&middot;&nbsp;&nbsp;&nbsp; infection of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp; skin changes including change in colour, peeling, redness, itching and sweating</p><p>&nbsp;</p><p><strong>Uncommon side effects that may show up in laboratory tests:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; changes in the shape of red blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp; increased number of platelets</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased levels of calcium</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased number of red blood cells (anaemia) cause by excessive</p><p>&middot;&nbsp;&nbsp;&nbsp; destruction of red blood cells (haemolytic anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp; increased number of myelocytes</p><p>&middot;&nbsp;&nbsp;&nbsp; increased band neutrophils</p><p>&middot;&nbsp;&nbsp;&nbsp; increased blood urea</p><p>&middot;&nbsp;&nbsp;&nbsp; increased levels of blood albumin</p><p>&middot;&nbsp;&nbsp;&nbsp; increased levels of total protein</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased levels of blood albumin</p><p>&middot;&nbsp;&nbsp;&nbsp; increased pH of urine</p><p>&middot;&nbsp;&nbsp;&nbsp; increased haemaglobin level</p><p>&nbsp;</p><p><strong>The following additional side effects have been reported to be associated with treatment with Revolade in children (aged 1 to 17 years) with ITP:</strong></p><p>If these side effects become severe, please tell your doctor, pharmacist or nurse.</p><p><strong>Very common side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; These may affect <strong>more than 1 in 10 </strong>children:</p><p>&middot;&nbsp;&nbsp;&nbsp; infection in the nose, sinuses, throat and upper airways, common cold (upper respiratory tract infection)</p><p>&middot;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp; high temperature</p><p>&middot;&nbsp; feeling sick (nausea)</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10 </strong>children:</p><p>&middot;&nbsp;&nbsp;&nbsp; difficulty in sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp; toothache</p><p>&middot;&nbsp;&nbsp;&nbsp; pain in the nose and throat</p><p>&middot;&nbsp;&nbsp;&nbsp; itchy, runny or blocked nose</p><p>&middot;&nbsp;&nbsp;&nbsp; sore throat, runny nose, nasal congestion and sneezing</p><p>&middot;&nbsp;&nbsp;&nbsp; mouth problems including dry mouth, sore mouth, sensitive tongue, bleeding gums, mouth</p><p>&middot;&nbsp;&nbsp;&nbsp; ulcers</p><p>&nbsp;</p><p><strong>The following side effects have been reported to be associated with treatment with Revolade in combination with peginterferon and ribavirin in patients with HCV:</strong></p><p><strong>Very common side effects</strong></p><p>These may affect <strong>more than 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling sick (nausea), diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp; muscle pain, muscle weakness</p><p>&middot;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp; lack of energy</p><p>&middot;&nbsp;&nbsp;&nbsp; high temperature</p><p>&middot;&nbsp;&nbsp;&nbsp; unusual hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling weak</p><p>&middot;&nbsp;&nbsp;&nbsp; flu-like illness</p><p>&middot;&nbsp;&nbsp;&nbsp; swelling in the hands or feet</p><p>&middot;&nbsp;&nbsp;&nbsp; chills</p><p>&nbsp;</p><p><strong>Very common side effects that may show up in blood tests:</strong></p><p>decreased number of red blood cells (anaemia)</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp; infection of the urinary system</p><p>&middot;&nbsp;&nbsp;&nbsp; inflammation of the nasal passages, throat and mouth, flu-like symptoms, dry mouth, sore or inflamed mouth, toothache</p><p>&middot;&nbsp;&nbsp;&nbsp; weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp; sleep disorders, abnormal drowsiness, depression, anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp; dizziness, problems with attention and memory, change in mood</p><p>&middot;&nbsp;&nbsp;&nbsp; tingling or numbness of the hands or feet</p><p>&middot;&nbsp;&nbsp;&nbsp; fever, headache</p><p>&middot;&nbsp;&nbsp;&nbsp; eye problems, including cloudy lens in the eye (cataract), dry eye, small yellow deposits in the retina, yellowing of the whites of the eye</p><p>&middot;&nbsp;&nbsp;&nbsp; bleeding of the retina</p><p>&middot;&nbsp;&nbsp;&nbsp; spinning sensation (vertigo)</p><p>&middot;&nbsp;&nbsp;&nbsp; fast or irregular heartbeat (palpitations), shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp; cough bringing up phlegm, runny nose, flu, cold sore, sore throat and discomfort when swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp; digestive system problems, including being sick (vomiting), stomach pain, indigestion, constipation, swollen stomach, taste disturbances, inflammation of the stomach, piles (haemorrhoids), irritation of the gut</p><p>&middot;&nbsp;&nbsp;&nbsp; toothache</p><p>&middot;&nbsp;&nbsp;&nbsp; liver problems, including blood clot, tumour in the liver (see &lsquo;Liver problems&rsquo; earlier in section 2)</p><p>&middot;&nbsp;&nbsp;&nbsp; skin changes, including rash, dry skin, eczema, redness of the skin, itching, excessive sweating, unusual skin growths</p><p>&middot;&nbsp;&nbsp;&nbsp; joint pain, back pain, bone pain, pain in the hands or feet, muscle spasms</p><p>&middot;&nbsp;&nbsp;&nbsp; irritability, generally feeling unwell, chest pain and discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp; infection in the nose, sinuses, throat and upper airways, common cold (upper respiratory tract infection)</p><p>&middot;&nbsp;&nbsp;&nbsp; depression, anxiety, sleep problems, nervousness</p><p>&nbsp;</p><p><strong>Common side effects that may show up in blood tests:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; increased blood sugar (glucose)</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased number of white blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased level of blood proteins</p><p>&middot;&nbsp;&nbsp;&nbsp; increased levels of blood bilirubin (a substance produced by the liver)</p><p>&middot;&nbsp;&nbsp;&nbsp; changes in the enzymes that control blood clotting</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong></p><p>These may affect <strong>up to 1 in 100 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp; painful urination</p><p>&middot;&nbsp;&nbsp;&nbsp; disturbances of heart rhythm (QT prolongation)</p><p>&middot;&nbsp;&nbsp;&nbsp; stomach flu (gastroenteritis)</p><p>&middot;&nbsp;&nbsp;&nbsp; skin changes including change in colour, peeling, redness, itching and sweating.</p><p>&middot;&nbsp;&nbsp;&nbsp; yellowing of the whites of the eyes or skin (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp; swollen blood vessels and bleeding in the gullet (oesophagus)</p><p>&middot;&nbsp;&nbsp;&nbsp; rash, bruising at the injection site</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased number of red blood cells (anaemia) caused by excessive destruction of red blood cells (haemolytic anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp; confusion, agitation</p><p>&middot;&nbsp;&nbsp;&nbsp; liver injury due to medication</p><p>&nbsp;</p><p><strong>The following side effects have been reported to be associated with treatment with Revolade in patients with severe aplastic anaemia (SAA):</strong></p><p>If these side effects become severe, please tell your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><strong>Very common side effects</strong></p><p>These may affect <strong>more than 1 in 10 </strong>people.</p><p>&middot;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp; pain in the nose and throat</p><p>&middot;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp; joint pain (arthralgia)</p><p>&middot;&nbsp;&nbsp;&nbsp; pain in extremities (arms, legs, hands and feet)</p><p>&middot;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling very tired (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp; itchy eyes</p><p>&middot;&nbsp;&nbsp;&nbsp; blisters in the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp; muscle spasms</p><p>&nbsp;</p><p><strong>Very common side effects that may show up in the blood tests</strong></p><p>abnormal changes to the cells in your bone marrow</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p>These may affect up to <strong>1 in 10 </strong>people.</p><p>&middot;&nbsp;&nbsp;&nbsp; anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling cold</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling unwell</p><p>&middot;&nbsp;&nbsp;&nbsp; eye problems including blurred vision, cloudy lens in the eye (cataract), spots or deposits in eye (vitreous floaters), dry eye, itchy eye, yellowing of the whites of the eyes or skin</p><p>&middot;&nbsp;&nbsp;&nbsp; nose bleed</p><p>&middot;&nbsp;&nbsp;&nbsp; bleeding of the gums</p><p>&middot;&nbsp;&nbsp;&nbsp; digestive system problems including being sick (vomiting), change in appetite (increased or decreased), stomach pain/discomfort, swollen stomach, passing wind, change in stool colour</p><p>&middot;&nbsp;&nbsp;&nbsp; fainting</p><p>&middot;&nbsp;&nbsp;&nbsp; skin problems including small red or purple spots caused by bleeding into the skin (petechiae) rash, itching, skin lesion</p><p>&middot;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp; muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp; bone pain</p><p>&middot;&nbsp;&nbsp;&nbsp; weakness (asthenia)</p><p>&middot;&nbsp;&nbsp;&nbsp; swelling of the lower limbs due to the accumulation of fluids</p><p>&middot;&nbsp;&nbsp;&nbsp; abnormal colored urine</p><p>&middot;&nbsp;&nbsp;&nbsp; interruption in blood supply to spleen (splenic infarction)</p><p>&middot;&nbsp;&nbsp;&nbsp; runny nose</p><p>&nbsp;</p><p><strong>Common side effects that may show up in the blood tests</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; increase in enzymes due to muscle breakdown (creatine phosphokinase)</p><p>&middot;&nbsp;&nbsp;&nbsp; accumulation of iron in the body (iron overload)</p><p>&middot;&nbsp;&nbsp;&nbsp; decrease in blood sugar levels (hypoglycaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp; increased levels of bilirubin (a substance produced by the liver)</p><p>&middot;&nbsp;&nbsp;&nbsp; increased levels of liver enzymes (aspartate aminotransferase (AST))</p><p>&middot;&nbsp;&nbsp;&nbsp; decreased levels of white blood cells</p><p>&nbsp;</p><p><strong>Side effects with frequency not known</strong></p><p>Frequency cannot be estimated from the available data</p><p>&middot;&nbsp;&nbsp;&nbsp; skin discolouration</p><p>&middot;&nbsp;&nbsp;&nbsp; darkening of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp; yellowing of the skin and eyes, tenderness around the liver</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date, which is stated on the carton and the blister.</p><p>&middot;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&middot;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C/Store below 30&deg;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Revolade is eltrombopag.</p><p>&nbsp;</p><p><strong>25&nbsp;mg film-coated tablets</strong></p><p>Each film-coated tablet contains eltrombopag olamine equivalent to 25&nbsp;mg eltrombopag.</p><p><u>&nbsp;</u></p><p><strong>50&nbsp;mg film-coated tablets</strong></p><p>Each film-coated tablet contains eltrombopag olamine equivalent to 50&nbsp;mg eltrombopag.</p><p>&nbsp;</p><p>&nbsp;</p><p>The other ingredients are: hypromellose, macrogol 400, magnesium stearate, mannitol (E421), microcrystalline cellulose, povidone, sodium starch glycolate, titanium dioxide (E171).</p><p>&nbsp;</p><p>Revolade &nbsp;25&nbsp;mg film-coated tablets also contain polysorbate 80 (E433).</p><p>&nbsp;</p><p>Revolade 50&nbsp;mg film-coated tablets also contain iron oxide red (E172) and iron oxide yellow (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Revolade 25 mg film-coated tablets are round, biconvex, white, debossed with ‘GS NX3’ and ‘25’ on one side.

Revolade 50 mg film-coated tablets are round, biconvex, brown, debossed with ‘GS UFU’ and ‘50’ on one side.

	
They are supplied in aluminum blisters in a carton containing 14 or 28 film-coated tablets and multipacks containg 84 (3 packs of 28) film-coated tablets).

Not all pack sizes may be available in your country.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by swissmedic in 12/2023

To report any side effect(s):
Saudi Arabia
Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):
SFDA call center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

Patient Safety Department Novartis Consulting AG - Saudi Arabia:
Toll Free Number: 8001240078
Phone: +966112658100
Fax: +966112658107
Email: adverse.events@novartis.com

Other GCC States:
- Please contact the relevant competent authority.

To report any complaint(s) : complaints.ksa@novartis.com

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">یحتوي عقار ریفوليد على المادة الفعالة الترومبوباج، والذي ینتمي إلى مجموعة من الأدویة تسُمى ناھضات مستقبلات الثرومبوبویتین. يحفز ريفوليد نخاع العظم (جزء من العظم الذي يصنع خلايا الدم) لإنتاج المزيد من الصفائح الدموية. یستخدم للمساعدة في زیادة عدد الصَّفائح الدمَّویة لدیك بالدم. الصفائح الدمَّویة ھي خلایا بالدمَّ تسُاعد على الحد من النزیف أو منعه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یسُتخدم عقار ریفوليد لعلاج اضطراب نزفي یُسمى نقص الصفائح الدَّمویة المناعیة (الإبتدائي) في المرضى من سن عام واحد فأكثر، ممن سبق أن تناولوا بالفعل أدویة أخرى (كورتیكوستیرویدات أو جلوُبولینات مَناعِیةَّ)، لم تُجدِ نفعاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث فرفریة نقص الصفائح الدمَّویة المناعیة نتیجة انخفاض عدد الصَّفائح الدمَّویة بالدم (نقص الصفائح الدمَّویة). لدى الأشخاص المصابین بفرفریة نقص الصفائح الدمَّویة المناعیة مخاطر متزایدة لحدوث النزیف. الأعراض التي یمكن أن یلاحظھا المرضى المصابون بفرفریة نقص الصفائح الدمَّویة المناعیة ھي الحَبَرات (نقاط حمراء دائریة مسطحة دقیقة الحجم تحت الجلد)، والكدمات، ونزیف من الأنف (رعاف)، ونزیف اللثة وعدم القدرة على التحَّكم بالنزیف عند إصابتھم بقطع أو جرح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یمكن أیضًا استخدام عقار ریفوليد لعلاج تعداد الصفائح الدَّمویة المنخفض (نقص الصفائح الدمَّویة) في البالغی الذین یعانون من عدوى التھاب الكبد الفیروسي من النوع &quot;سي&quot;، إذا كان لدیھم مشاكل مع الآثار الجانبیة أثناء العلاج بالإنترفیرون. یعاني العدید من الأشخاص المصابین بعدوى فیروس الالتھاب الكبدي من النوع &quot;سي&quot; من انخفاض تعداد الصفائح الدمَّویة، لیس فقط كنتیجة للمرض، ولكن أیضًا بسبب بعض الأدویة المضادة للفیروسات التي تسُتخدم لعلاج المرض. قد یجعل تناوُل عقار ریفولاد من السھل علیك إكمال مسار كامل من العلاج بالأدویة المضادة للفیروسات (بیج إنترفیرون وریبافیرین).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یمُكن استخدام عقار ریفوليد أیضًا لعلاج المرضى البالغین ممن یعانون من نقص تعداد خلایا الدمَّ الناتج عن فقر ھو مرض یتلف فیھ النخاع العظمي ویتسبب في نقص خلایا الدم SAA.&quot;SAA&quot; الدمَّ غیر التنسجي الشدید الحمراء (فقر الدم) وخلایا الدم البیضاء (قلة الكریات البیض) والصفائح الدمویة (نقص الصفیحات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من أجل علاج الخط الأول من فقر الدَّم غیرالتنسجي الحاد المكتسب &quot;SAA&quot; بالاشتراك مع العلاج القياسي المثبط للمناعة لدى المرضى البالغین والأطفال الذین تتراوح أعمارھم بین عامین وأكثر ممن ھم غیر مناسبین لزراعة الخلایا الجذعیة المكونة للدم في وقت التشخیص.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;</strong></p><p dir="RTL"><strong>أ</strong><strong>.</strong><strong>&nbsp; موانع استعمال ريفوليد</strong><strong>:</strong></p><p dir="RTL">&middot;<strong> إذا ﻛﻨﺖ</strong><strong> ﺗﻌﺎﻧﻲ</strong><strong> ﻣﻦ</strong><strong> ﺣﺴﺎﺳﯿﺔ</strong> ﺗﺠﺎه اﻟﺘﺮوﻣﺒﻮﺑﺎج أو ﺗﺠﺎه أي ﻣﻜﻮن ﻣﻦ اﻟﻤﻜﻮﻧﺎت اﻷﺧﺮى ﺑﮭﺬا اﻟـﺪﱠواء) اﻟﻤﺪرﺟـﺔ ﻓـﻲ قسم: 6 تحت عنوان &quot;محتويات دواء ريفوليد&quot;).</p><p dir="RTL"><strong>ﯾُﺮﺟﻰ</strong><strong>&nbsp;ﻣﺮاﺟﻌﺔ</strong><strong>&nbsp;طﺒﯿﺒﻚ</strong>&nbsp;إذا&nbsp;ﻛﻨﺖ&nbsp;ﺗﻌﺘﻘﺪ&nbsp;أن هذا ينطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ب.&nbsp; الاحتياطات عند استعمال ريفوليد:</p><p>إذا كان أي مما يلي ينطبق عليك/ على طفلك، تحدث مع طبيبك أو الصيدلي ﻗﺒﻞ ﺗﻨﺎول&nbsp;ﻋﻘﺎر رﯾﻔﻮليد:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ<strong> </strong><strong>ﻣﺸﺎﻛﻞ</strong><strong> </strong><strong>ﺑﺎﻟﻜﺒﺪ</strong>. اﻷﺷﺨﺎص ﻣﻤﻦ ﻟـﺪﯾﮭﻢ اﻧﺨﻔـﺎض ﺑﻌـﺪد اﻟﺼـﻔﺎﺋﺢ اﻟﺪﱠﻣﻮﯾـﺔ ﺑﺎﻹﺿـﺎﻓﺔ إﻟـﻰ ﻣـﺮض ﻣﺰﻣﻦ ﻣﺘﻘﺪم )طﻮﯾﻞ اﻷﻣﺪ( ﺑﺎﻟﻜﺒﺪ، ﯾﻜﻮﻧﻮن أﻛﺜﺮ ﻋﺮﺿﺔ ﻟﻤﺨﺎطﺮ ﺣﺪوث اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿـﺔ، ﺑﻤـﺎ ﻓـﻲ ذﻟـﻚ ﺗﻠـﻒ اﻟﻜﺒـﺪ المهدد للحياة وتكوّن جلطات الدم. إذا رأى طبیبك أنَّ فوائد تناوُل عقار ریفوليد تفوق المخاطر، فستتم متابعتك عن كثب أثناء العلاج.</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كنت تعاني من مشاكل في الكلى فيجب استخدام ريفوليد بحذر</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت معرضًا لخطر تكوُّن <strong>جلطات</strong><strong> </strong><strong>الدَّم</strong><strong> </strong>في أوردتك أو شرایینك، أو كنت تعرف أنَّ تكونّ جلطات الدمَّ شائعة في عائلتك</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تكون <strong>أكثر عرضة لخطر تجلط الدَّم في الحالات التاَّل</strong><strong>ی</strong><strong>ة</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع تقدم سنك.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا اضطررت للبقاء في السَّریر لفترة طویلة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بالسرطان.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تتناولین حبوب منع الحمل أو العلاج بالھرمونات التعویضیة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أجریت عملیة جراحیة مؤخرًا أو تعرضت لإصابة جسدیة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من زیادة مفرطة في الوزن (السمنة).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مدخناً.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمرض متقدم ومزمن بالكبد.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبیبك قبل بدء العلاج إذا انطبق علیك أيٌّ من ھذه الحالات. یجب ألّا تتناول عقار ریفوليد إلّا إذا رأى طبیبك أنَّ الفوائد المتوقعة تفوق خطر تكوَن الجلطات الدمَّویة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بالمیاه البیضاء (إعتام عدسة العین).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بحالة مرضیة أخرى بالدَّم، مثل متلازمة خلل التَّنسج النخاعي &quot;MDS&quot;. سيقوم طبيبك بإجراء اختبارات؛ للتَّأكد من عدم إصابتك بھذه الحالة المرضیة بالدمَّ قبل أن تبدأ العلاج بعقار ریفوليد. إذا كنت مصاباً بمتلازمة خلل التنَّسج النخاعي وتناولت عقار ریفوليد، فقد تسوء المتلازمة لدیك.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبیبك إذا انطبق علیك أيٌّ من ھذه الحالات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﻓﺤﺺ</strong><strong>&nbsp;اﻟﻌﯿﻦ</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ﺳﯿﻮﺻﻲ&nbsp;طﺒﯿﺒﻚ&nbsp;ﺑﺄن&nbsp;ﯾﺘﻢ&nbsp;ﻓﺤﺼﻚ&nbsp;ﺗﺤﺴﺒًﺎ&nbsp;ﻟﻺﺻﺎﺑﺔ ﺑﺎﻟﻤﯿﺎه&nbsp;اﻟﺒﯿﻀﺎء.&nbsp;إذا&nbsp;ﻟﻢ&nbsp;ﺗﻜﻦ&nbsp;ﺗﺨﻀﻊ&nbsp;لاختبارات روتينية&nbsp;ﻟﻠﻌـﯿﻦ،&nbsp;ﻓﯿﺠـﺐ&nbsp;ﻋﻠـﻰ&nbsp;طﺒﯿﺒﻚ&nbsp;ﺗﺮﺗﯿﺐ&nbsp;إﺟﺮاء&nbsp;اﺧﺘﺒﺎرات&nbsp;ﻣﻨﺘﻈﻤﺔ.&nbsp;يمكن أيضًا التحقق ﻣـﻦ&nbsp;ﺣـﺪوث&nbsp;أي&nbsp;ﻧﺰﯾـﻒ&nbsp;ﻓـﻲ&nbsp;أو&nbsp;ﺣـﻮل&nbsp;ﺷـﺒﻜﯿﺔ&nbsp;اﻟﻌـﯿﻦ&nbsp;ﻟـﺪﯾﻚ&nbsp;)طﺒﻘــﺔ&nbsp;اﻟﺨﻼﯾﺎ اﻟﺤﺴﺎﺳﺔ ﻟﻠﻀﻮء اﻟﻤﻮﺟﻮدة ﺑﺎﻟﺠﺰء اﻟﺨﻠﻔﻲ ﻣﻦ اﻟﻌﯿﻦ.(</p><p>&nbsp;</p><p dir="RTL"><strong>ﺳﺘﺤﺘﺎج</strong><strong>&nbsp;ﻹﺟﺮاء اﺧﺘﺒﺎرات</strong><strong>&nbsp;ﻣﻨﺘﻈﻤﺔ</strong></p><p dir="RTL">سيقوم طبيبك بإجراء اختبارات الدم، للتحقق من خلال الدم لديك، بما في ذلك الصفاحئح الدموية، قبل أن تبدأ في تناول عقار ريفوليد. سوف يتكرر إجراء هذه الاختبارات على فترات أثناء تناولك العقار.</p><p>&nbsp;</p><p dir="RTL"><strong>اﺧﺘﺒﺎرات</strong><strong> </strong><strong>اﻟدم</strong><strong> </strong><strong>ﻟﻮظﺎﺋﻒ</strong><strong> </strong><strong>اﻟﻜﺒﺪ</strong></p><p dir="RTL">یمكن أن یسبب عقار ریفوليد نتائج في اختبار الدَّم قد تكون علامات على تلف الكبد - زیادة في بعض إنزیمات الكبد، خاصة البیلیروبین والناقلات الأمینیة الألانینیة والأسبارتیة. یمكن أن تزداد بعض مشاكل الكبد سوءًا إذا كنت تتناول علاجات قائمة على الإنترفیرون جنبًا إلى جنب مع عقار ریفوليد لعلاج انخفاض عدد الصفائح الدمَّویة بسبب التھاب الكبد الفیروسي من النوع &quot;سي&quot;.</p><p dir="RTL">&nbsp;</p><p>سوف یتم إجراء اختبارات لدیك بالدَّم؛ للتَّحقق من وظائف الكبد لدیك قبل البدء في تناوُل عقار ریفوليد وعلى فترات أثناء تناولك العقار. قد تحتاج إلى التوَّقف عن تناوُل عقار ریفوليد إذا ازداد مقدار ھذه المواد أكثر من اللازم، أو إذا ظھرت علیك علامات أخرى لتلف الكبد.</p><p dir="RTL">&middot;<strong> اﻗﺮأ</strong><strong> اﻟﻤﻌﻠﻮﻣﺎت</strong><strong> </strong><strong>&quot;</strong><strong><em>ﻣﺸﺎﻛﻞ</em></strong><strong><em> </em></strong><strong><em>اﻟﻜﺒﺪ</em></strong><strong>&quot;</strong><strong> ﻓﻲ</strong><strong> اﻟﻘﺴﻢ</strong><strong> </strong><strong>4</strong><strong> ﻣﻦ</strong><strong> ھﺬه</strong><strong> اﻟﻨﱠﺸﺮة</strong><strong>.</strong></p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اختبارات الدَّم لتعداد الصَّفائح الدَّموية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا توقفت عن تناوُل عقار ریفوليد، من المرجح أن ینخفض تعداد الصَّفائح الدمَّویة لدیك مرة أخرى في غضون عدة أیام.</p><p dir="RTL">ستتم مراقبة تعداد الصَّفائح الدمَّویة، وسوف یناقش طبیبك الاحتیاطات المناسبة معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد یؤُدي الارتفاع الشَّدید بتعداد الصَّفائح الدمَّویة إلى زیادة خطر تجلط الدمَّ. ومع ذلك، ھناك إمكانیة لتكو نّ جلطات دمویة</p><p dir="RTL">مع وجود تعداد طبیعي أو حتى منخفض للصَّفائح الدَّمویة. سیقوم طبیبك بتعدیل جرعتك من عقار ریفوليد؛ لیتأكد من عدم</p><p dir="RTL">ارتفاع تعداد الصفائح الدمَّویة لدیك أكثر من اللازم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>احصل على المساعدة الطبية على الفور </strong>إذا عانیت من أيّ من علامات تكوّن <strong>الجلطة الدَّمو</strong><strong>ية</strong>ھذه:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تورم</strong>، <strong>ألم </strong>أو إیلام عند الضغط في <strong>ساق واحدة</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ضیق مفاجئ في التنَّفس</strong>، خاصةً عندما یكون مصحوبًا بألم حاد في الصَّدر أو سرعة في التَّنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن (المعدة)، تضخم بالبطن، ووجود دم في البراز الخاص بك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تليف الكبد، فهناك خطر تشكل جلطة دموية في الشريان المؤدي إلى الكبد (تخثر الوريد البابي). تشمل المضاعفات الخطيرة الناجمة عن بعض أنواع جلطات الدم جلطات الدم في الرئتين أو النوبات القلبية أو السكتات الدماغية. سيقوم طبيبك بفحص عدد الصفائح الدموية لديك ويضبط جرعتك أو يوقف تناول ريفولد إذا كان عدد الصفائح الدموية مرتفعا جدا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من علامات خلل في وظائف الكبد مثل اصفرار الجلد أو الملتحمة في العينين (يرقان)، لون داكن غير عادي للبول، تعب غير عادي، ألم في الجزء العلوي الأيمن من البطن. قد يؤدي ريفولد إلى إتلاف الكبد وحتى إلى الإصابة بأمراض تهدد الحياة.</p><p>&nbsp;</p><p dir="RTL"><strong>المراقبة أثناء علاجك بـريفوليد</strong></p><p dir="RTL">&nbsp;</p><p>ا<strong>ختبارات لفحص نخاع العظام لدی</strong><strong>ك</strong></p><p>في الأشخاص الذین یعانون من مشاكل لدیھم بالنخاع العظمي، یمكن أن تُؤدي عقاقیر مثل عقار ریفوليد إلى تفاقم ھذه</p><p>المشاكل لدیھم. علامات حدوث تغیرُّاتٍ بالنخاع العظمي قد تظھر في صورة نتائج غیر طبیعیة في اختبارات الدمَّ لدیك. قد یقوم طبیبك أیضًا بإجراء اختبارات لفحص النخاع العظمي لدیك بشكلٍ مباشر أثناء العلاج بعقار ریفوليد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p><strong>فحوصات لنزيف الجھاز الھضمي</strong></p><p>إذا كنت تتناول العلاجات القائمة على الإنترفیرون جنباً إلى جنب مع عقار ریفوليد، ستتم مراقبتك لرصد أي علامات للنزیف بالمعدة أو الأمعاء لدیك بعد توقفك عن تناول عقار ریفوليد.</p><p>&nbsp;</p><p dir="RTL"><strong>مراقبة القلب</strong></p><p dir="RTL">قد یرى طبیبك أنه من الضَّروري مراقبة قلبك أثناء العلاج بعقار ریفوليد ویجري اختبار تخطیط القلب الكھربائي .&quot;ECG&quot;</p><p dir="RTL">&nbsp;</p><p><strong>الأطفال والمراھقون</strong></p><p>لا یُوصى باستخدام عقار ریفوليد للأطفال الذین یعانون من فرفریة نقص الصفائح الدمَّویة المناعیة ممن تقل أعمارھم عن عامٍ واحد. كما أنه لا ینصح باستخدامه في الأشخاص دون سن 18 عامًا الذین یعانون من انخفاض تعداد الصفائح الدمَّویة بسبب التھاب الكبد من النوع &quot;سي&quot; أو فقر الدمَّ غیر التنسجي الشَّدید.</p><p>&nbsp;</p><p><strong>أ. تناوُل أدویة أخرى، أو مكملات عشبیة أو غذائیة</strong></p><p>یرُجى إبلاغ طبیبك أو الصیدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أیَّة أدویة أخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>تتداخل بعض الأدویة الیومیة مع عقار ریفوليد</strong> - بما في ذلك الأدویة الوصفیة وغیر الوصفیة والأدویة المحتویة على</p><p dir="RTL">المعادن. تشمل ھذه الأدویة:</p><p dir="RTL">&bull; &nbsp;الأدویة المضادة للحموضة المستخدمة لعلاج عسر الھضم أو الحموضة أو قرح المعدة (انظر أیضًا &quot; متى تتناول الدَّواء&quot; في القسم 3)</p><p dir="RTL">&bull; &nbsp;الأدویة التي تسمى بالستاتینات والمستخدمة لخفض نسبة الكولیسترول.</p><p dir="RTL">&bull; &nbsp;بعض الأدویة المستخدمة لعلاج عدوى فیروس نقص المناعة البشري، مثل: لوبینافیر و/ أو ریتونافیر.</p><p dir="RTL">&bull; &nbsp;سیكلوسبورین المستخدم في إطار عملیات زرع الأعضاء أو أمراض المناعة.</p><p dir="RTL">&bull; &nbsp;المعادن مثل: الحدید، والكالسیوم، والماغنسیوم، والألومنیوم، والسیلینیوم والزِّنْك، والتي یمكن أن تتواجد في المكملات الغذائیة المحتویة على الفیتامینات والمعادن (انظر أیضًا &quot; متى تتناول الدَّواء&quot; في القسم 3)</p><p dir="RTL">&bull; &nbsp;أدویة مثل میثوتریكسات وتوبوتیكان، المستخدمة لعلاج السرطان.</p><p dir="RTL">&bull; &nbsp;إذا تناولت أيًا من ھذه الأدویة، <strong>فتحدَّث إلى طبیبك</strong>. یجب تجنب تناوُل بعضھا مع عقار ریفوليد، أو قد تحتاج إلى &nbsp;تعدیل الجرعة، أو قد تحتاج إلى تغییر توقیت تناوُلھا. سیقوم طبیبك بمراجعة الأدویة التي تتناولھا، واقتراح بدائل مناسبة إذا لزم الأمر</p><p dir="RTL">&nbsp;</p><p>إذا كنت تتناول أیضًا أدویة للوقایة من تكونّ الجلطات الدَّمویة، فھناك خطورة أكبر لحدوث نزیف. سیقوم طبیبك بمناقشة ذلك معك.</p><p>&nbsp;</p><p>إذا كنت تتناول الكورتیكوستیرویدات، ودانازول، و/ أو أزاثیوبرین، فقد تحتاج إلى تناوُل جرعة أقل أو التوَّقف عن تناوُلھم أثناء تناولك لعقار ريفوليد.</p><p>&nbsp;</p><p dir="RTL"><strong>ب. تناوُل عقار ریفولاد مع الأطعمة والمشروبات</strong></p><p dir="RTL">لا تتناول عقار ریفولاد مع منتجات أو مشروبات الألبان؛ حیث إنَّ الكالسیوم في منتجات الألبان یُؤثر على امتصاص الدوَّاء. لمزید من المعلومات، انظر &quot; <strong>متى تتناول الدَّواء</strong>&quot; في القسم 3</p><p>&nbsp;</p><p dir="RTL"><strong>ج. الحمل والرضاعة الطبیعیة</strong></p><p dir="RTL">لا تستخدمي عقار ریفوليد إذا كنتِ حاملاً ، ما لم یوصِ طبیبكِ بذلك تحدیداً. تأثیر عقار ریفوليد أثناء الحمل غیر معروف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; &nbsp;إذا كنتِ حاملاً ، أو تعتقدین أنكِ قد تكونین حاملاً أو تخططین للحمل، فأخبري طبیبكِ .</p><p dir="RTL">&bull; &nbsp;استخدمي وسیلة منع حمل موثوق بھا أثناء تناوُلكِ عقار ریفوليد؛ لمنع الحمل.</p><p dir="RTL">&bull; &nbsp;إذا أصبحتِ حاملاً أثناء العلاج بعقار ریفوليد، فأخبري طبیبكِ .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تجنبي الرضاعة الطبیعیة أثناء تناوُلكِ لعقار ریفوليد</strong><strong>.</strong> من غیر المعروف ما إذا كان عقار ریفولاد یمر في لبن الأم أم لا.</p><p dir="RTL">&bull; &nbsp;أخبري طبیبك <strong>إذا كنتِ مرضعًا </strong>أو تنوین الإرضاع.</p><p>&nbsp;</p><p dir="RTL"><strong>د</strong><strong>. </strong><strong>القیادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">یمكن أن یجعلك عقار ریفوليد تشعر بالدوخة وله آثار جانبیة أخرى تجعلك أقل یقظة.</p><p dir="RTL">&bull; &nbsp;تجنب القیادة أو استخدام الآلات، إلا إذا كنت متأكداً من أنك لم تتأثر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا ھذا الدَّواء كما أخبرك طبیبك بالضبط. راجع طبیبك أو الصیدلي الخاص بك إذا لم تكن متأكدًا من كیفیة التناول.</p><p dir="RTL">لا تقُم بتغییر الجرعة أو الجدول الزَّمني لتناوُل عقار ریفوليد ما لم ینصحك طبیبك أو الصیدلي الخاص بك بذلك. سوف تكون تحت رعایة طبیب ذي خبرة متخصصة في علاج حالتك أثناء تناوُلك لعقار ریفوليد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما الكمیة التي یجب أن تتناولھا؟</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لعلاج فرفریة نقص الصَّفائح الدَّمویة المناعیة</strong></p><p dir="RTL"><strong>البالغون والأطفال</strong> (بعمر 6 إلى 17 عامًا) - جرعة البدء المعتادة لعلاج فرفریة نقص الصَّفائح الدمَّویة المناعیة ھي <strong>قرص</strong><strong> </strong><strong>&nbsp;</strong><strong>واحد 50 مجم</strong> من عقار ریفوليد یومیا. إذا كنت من أصول شٍرق آسیویة (مثل: الصینیین أو الیابانیین أو التایوانیین أوالتایلاندیین أو الكوریین) فقد تحتاج إلى البدء بجرعة <strong>أقل قدرھا 25 مجم</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong> (بعمر 1 إلى 5 أعوام) - جرعة البدء المعتادة لعلاج فرفریة نقص الصَّفائح الدمَّویة المناعیة ھي <strong>قرص واحد 25</strong><strong> </strong><strong>مجم</strong> من عقار ریفوليد یومیا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج التھاب الكبد من النوع &quot;سي</strong><strong>&quot;</strong></p><p dir="RTL"><strong>البالغون</strong> - جرعة البدء المعتادة لعلاج التھاب الكبد من النوع &quot;سي&quot; <strong>ھي قرص واحد 25 مجم</strong> من عقار ریفوليد یومیا. إذا كنت من أصول شرق آسیویة (مثل: الصینیین أو الیابانیین أو التایوانیین أوالتایلاندیین أو الكوریین) فستبدأ بنفس <strong>الجرعة</strong> <strong>25 مجم</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لعلاج فقر الدَّم غیر التَّنسجي الشَّدید</strong></p><p dir="RTL"><strong>البالغون</strong> - جرعة البدء المعتادة لعلاج فقر الدَّم غیر التنسجي الشَّدید ھي قرص واحد <strong>50 مجم من عقار</strong> ریفوليد یومیا. إذا كنت من أصول شرق آسیویة (مثل: الصینیین أو الیابانیین أو التایوانیین أو التایلاندیین أو الكوریین)، فقد تحتاج إلى البدء <strong>بجرعة أقل قدرھا 25 مجم.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد یستغرق عقار ریفوليد فترة تتراوح بین أسبوع إلى أسبوعین قبل أن یبدأ في العمل. قد یوُصى طبیبك بتغییر جرعتك الیومیة بناءً على استجابتك لعقار ریفوليد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كیفیة تناوُل الأقراص</strong></p><p dir="RTL">ابتلع القرص كاملاً ، مع بعض الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى تتناول الدَّواء؟</strong></p><p dir="RTL">احرص على تناوله:&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في ال 4 ساعات السابقة لتناول عقار ریفوليد</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخلال الساعتین التاَّلیتین لتناول عقار ریفوليد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أَلَّا تتناول أی مما يلي: </strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منتجات الألبان مثل: الجبن أو الزبدة أو الزبادي أو المثلجات.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحلیب أو الحلیب المخفوق، المشروبات التي تحتوي على الحلیب، أو الزبادي أو الكریمة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الحموضة، وھي نوع من الأدویة تستخدم لعلاج عسر الھضم والحموضة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المكملات الغذائیة المحتویة على الفیتامینات والمعادن بما في ذلك الحدید والكالسیوم والماغنسیوم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; والألومنیوم والسیلینیوم والزنك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا قمت بذلك، فلن یمتص جسمك الدَّواء بشكل صحیح.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:204.75pt;height:153.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="273" height="205" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لمزید من النصائح حول الأطعمة والمشروبات المناسبة، تحدَّث مع طبیبك</strong><strong>.</strong><strong>أ. إذا تناولت كمیة أكثر مما یجب من عقار ریفوليد</strong></p><p dir="RTL"><strong>یرُجى الاتصال بالطبیبٍ أو الصیدلي على الفور. </strong>اعرض لھم العبوة أو ھذه النَّشرة إذا أمكن.</p><p dir="RTL">سیتم مراقبتك لرصد أیة علامات أو أعراض للآثار الجانبیة وسیتم إعطاؤك العلاج المناسب على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. إذا أغفلت تناوُل عقار ریفوليد</strong></p><p dir="RTL">تناول الجرعة التاَّلیة في الموعد المعتاد. لا تتناول أكثر من جرعة واحدة من عقار ریفوليد في الیوم الواحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. إذا توقفت عن تناوُل عقار ریفوليد</strong></p><p dir="RTL">لا تتوقف عن تناوُل عقار ریفوليد دون التَّحدث إلى طبیبك. إذا أشار علیك طبیبك بوقف العلاج، عندئذ سیتم فحص تعداد</p><p dir="RTL">الصَّفائح الدمَّویة لدیك كل أسبوع لمدة أربعة أسابیع. انظر أیضًا &quot;حدوث نزیف أو كدمات بعد توقفك عن العلاج&quot; في القسم 4&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لدیك أیة أسئلة إضافیة حول استخدام ھذا الدوَّاء، فاستشر طبیبك أو الصیدلي الخاص بك</p><p dir="RTL">*لم یتم تسجیل مسحوق لإعداد محلول عن طریق الفم الذي یدعم الفئة العمریة من 1 إلى 5 سنوات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدویة، قد یسُبب ھذا الدوَّاء آثارًا جانبیة، على الرَّغم من عدم حدوثھا لدى الجمیع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض التي ینبغي الانتباه لھا: قم بزیارة الطبیب إذا أصُبت بھا</strong></p><p dir="RTL">یمكن أن تظھر علامات الآثار الجانبیة التي قد تكون خطیرة في الأشخاص الذین یتناولون عقار ریفوليد، إما لعلاج فرفریة نقص الصفائح الدمَّویة المناعیة أو انخفاض تعداد الصفائح الدمَّویة بسبب التھاب الكبد الفیروسي &quot;سي&quot;. <strong>من المھم إخبار</strong> <strong>الطبیب إذا ظھرت لدیك ھذه الأعراض</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ارتفاع خطر تكوّن الجلطات الدَّمویة</strong></p><p dir="RTL">قد یكون لدى بعض الأشخاص احتمالیة أعلى للإصابة بالجلطات الدمَّویة، ویمكن أن تتسبب أدویة مثل عقار ریفوليد في تفاقم ھذه المشكلة. إنَّ الانسداد المفاجئ لوعاءٍ دموي بواسطة جلطة دمویة ھو تأثیر جانبي غیر شائع وقد یُؤثر على ما یصل إلى شخص واحد من بین كل 100 شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>احصل على المساعدة الطبیة على الفور إذا ظھرت لدیك أي من علامات وأعراض تكوّن الجلطة الدَّمویة، مثل</strong><strong>:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم، ألم، حرارة، احمرار أو ألم عند الضغط في ساق واحدة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضیق مفاجئ في التنَّفس، خاصةً عندما یكون مصحوبًا بألم حاد في الصدر أو سرعة التَّنفس.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن (المعدة)، تضخم بالبطن، ووجود دم في البراز الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشاكل الكبد</strong></p><p dir="RTL">یمكن أن یُسبب عقار ریفولاد تغیرات تظھر في اختبارات الدَّم، وقد تكون علامات على تلف الكبد. مشاكل الكبد (ارتفاع مستوى الإنزیمات الذي یظھر في اختبارات الدمَّ) شائعة وقد تُؤثر على ما یصل إلى شخص واحد من بین كل 10 أشخاص. مشاكل الكبد الأخرى (عدم تدفق الصفراء بشكل صحیح) غیر شائعة وقد تُؤثر على ما یصل إلى شخص واحد من بین كل 100 شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كان لدیك أيٌّ من علامات مشاكل الكبد التاَّلیة</strong><strong>:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو اصفرار بیاض العینین (الیرقان).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بول داكن اللون بشكل غیر معتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الفشل الكلوي:</strong> ويشمل الانخفاض الشديد في إنتاج البول</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبیبك على الفور.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حدوث نزیف أو كدمات بعد توقفك عن العلاج</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">في غضون أسبوعین من التَّوقف عن تناوُل عقار ریفوليد، سینخفض تعداد الصَّفائح الدَّمویة لدیك عادةً ویتراجع إلى ما كان علیه قبل بدء تناوُل عقار ریفوليد. قد یزید انخفاض تعداد الصَّفائح الدمَّویة من خطر إصابتك بالنزیف أو التكَّدم. سیقوم طبیبك بالتحَّقق من تعداد الصَّفائح الدمَّویة لدیك لمدة 4 أسابیع على الأقل بعد توقفك عن تناوُل عقار ریفولاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبیبك</strong> إذا كان لدیك أي نزیف أو كدمات بعد إیقاف عقار ریفوليد.یُصاب بعض الأشخاص <strong>بنزیف في الجھاز الھضمي</strong> بعد توقفھم عن تناوُل بیج إنترفیرون، وریبافیرین، وعقار ریفوليد.</p><p dir="RTL">تشمل الأعراض ما یلي:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز أسود بلون القطران (یعُد تغیر لون البراز من الآثار الجانبیة غیر الشَّائعة التي قد تُؤثر على ما یصل إلى شخص واحد من بین كل 100 شخص).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم في البراز الخاص بك.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقیؤ الدَّم أو تقیؤ شيء شَبیه بالبن المطحون.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبیبك فورًا إذا كنت تعاني من أيٍّ من ھذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة المحتملة الأخرى في البالغین المصابین بفرفریة نقص الصفائح الدَّمویة المناعیة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبیة الشائعة جداً</strong></p><p dir="RTL">قد تُؤثر ھذه التَّأثیرات على <strong>ما یصل إلى شخص واحد من بین كل 10 </strong>أشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق والسعال وسيلان الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثیان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسھال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى في الأنف والجیوب الأنفیة والحلق والمجرى الھوائي العلوي ونزلات البرد الشائعة (عدوى الجھاز التنفسي العلوي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الشائعة جدا التي قد تظھر في اختبارات الدَّم</strong><strong>:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزیمات الكبد (الألانین أمنیو ترانسفیراز ((ALT)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الشائعة</strong></p><p dir="RTL">قد تُؤثر ھذه التَّأثیرات على <strong>ما یصل إلى شخص واحد من بین كل 10</strong> أشخاص:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات، تقلصات عضلیة، ضعف العضلات.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الظھر.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعظام.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو تنمیل بالیدین أو القدمین.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دورات طمث غزیرة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب الحلق والانزعاج عند البلع</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل العین بما في ذلك اختبار العین غیر الطبیعي ، وجفاف العین ، وآلام العین وعدم وضوح الرؤیة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقیؤ</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانفلونزا</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قروح البرد</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الإلتھاب الرئوي</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تھیج والتھاب (تورم) الجیوب الأنفیة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب (تورم) وعدوى التھاب اللوزتین في الرئتین والجیوب الأنفیة واللوزتین والأنف والحنجرة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب أنسجة اللثة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشھیة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالوخز أو الوخز أو التنمیل ، المعروف باسم &quot;المسامیر والإبر&quot;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الأذن</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وتورم وطراوة في إحدى ساقیك (عادة ما تكون في ربلة الساق) مع بشرة دافئة في المنطقة المصابة (علامات جلطة دمویة في الورید العمیق(</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم موضعي مليء بالدم من قطع حصل في الأوعیة الدمویة (ورم دموي)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الفم بما في ذلك جفاف الفم ، التھاب الفم ، لسان حساس ، نزیف اللثة و الفم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة المعدة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سیلان الأنف</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع أسنان</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة و طراوة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكبد</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یتغیر الجلد بما في ذلك التعرق الزائد ، الحكة الطفح الوعرة ، البقع الحمراء ، التغیرات في مظھر الجلد</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البول الرغوي أو الزبد أو الفقاعي (علامات البروتین في البول)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عموما شعور بتوعك ، ارتفاع في درجة الحرارة ، شعور بالحر</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في النوم والاكتئاب</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع نصفي</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الرؤیة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالدوران (الدوار)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غازات الأمعاء / الریح</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الشائعة جدا التي قد تظھر في اختبارات الدَّم</strong><strong>:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلایا الدم الحمراء (فقر الدم)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدمویة (نقص الصفیحات)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلایا الدم البیضاء</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الھیموغلوبین</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الحمضات</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة عدد خلایا الدم البیضاء (زیادة عدد الكریات البیضاء)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة مستویات حمض الیوریك</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستویات البوتاسیوم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة مستویات الكریاتینین</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة مستویات الفوسفاتیز القلویة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة إنزیمات الكبد (الأسبارتات أمینوتراز (AST))</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة في البیلیروبین (مادة ینتجھا الكبد)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة مستویات بعض البروتینات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة غیر الشائعة</strong></p><p dir="RTL">قد تُؤثر ھذه التَّأثیرات على <strong>ما یصل إلى شخص واحد من بین كل 100</strong> شخص:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب بإمداد الدمَّ إلى أحد أجزاء القلب.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضیق التنفس المفاجئ، خاصةً عندما یكون مصحوبًا بألم حاد بالصدر و/ أو سرعة التَّنفس، والذي قد یكون علامة لجلطة دمویة بالرئتین (انظر &quot;ارتفاع خطر تكوّن الجلطات الدَّمویة &quot; أعلاه في القسم &nbsp;4 )</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان وظیفة أحد أجزاء الرِّئة الناجم عن انسداد في شریان الرئة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالكبد، بما في ذلك اصفرار العینین والجلد (انظر: &quot;مشاكل الكبد&quot; أعلاه في القسم 4)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالكبد بسبب الأدویة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب، عدم انتظام ضربات القلب، تغییر لون الجلد إلى الأزرق.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النظَّم القلبي (إطالة زمن .(&quot;QT&quot;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دمویة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم مؤلم للمفاصل ناجم عن حمض الیوریك (النقرس).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الاھتمام، تغیرات مزاجیة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل مع التوازن والكلام و وظیفة العصب ، ارتعاش</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في العین بما في ذلك زیادة إنتاج الدموع ، عدسة غائمة في العین (إعتام عدسة العین) ، ونزیف في شبكیة العین</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالأنف، الحلق والجیوب الأنفیة، مشاكل في التنَّفس أثناء النوم.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الجھاز الھضمي بما في ذلك حركات الأمعاء المتكررة والتسمم الغذائي والدم في البراز</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزیف المستقیم ، دم في البراز ، انتفاخ بطني ، إمساك</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالفم، بما في ذلك جفاف أو ألم بالفم، حساسیة اللسان، نزیف اللثة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حروق شمسیة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو تورم حول الجرح. ،نزیف حول القسطرة (إن وجدت) في الجلد والشعور بوجود جسم غریب.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالكلى تتضمن: التھاب الكلى، والتبَّول المفرط في اللیل، والفشل الكلوي، وعدوى المسالك البولیة، ووجود</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلایا بیضاء في البول.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرقًا بارداً.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الجلدیة.</p><p dir="RTL">&middot;تغیرات بالجلد بما في ذلك: التَّعرق المفرط، طفح جلدي بارز یُسبب الحكة، بقع حمراء، تغیرات في مظھر الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة غیر الشَّائعة التي قد تظھر في اختبارات الدَّم</strong><strong>:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغییرات في شكل خلایا الدم الحمراء</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة عدد الصفائح الدمویة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستویات الكالسیوم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلایا الدم الحمراء (فقر الدم) الناجم عن التدمیر المفرط لخلایا الدم الحمراء) فقر الدم الانحلالي(</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة عدد الخلایا النخاعیة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة العدلات الفرقة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة الیوریا في الدم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة مستویات الألبومین في الدم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة مستویات البروتین الكلي</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستویات الألبومین في الدم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة درجة الحموضة في البول</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة مستوى الھیماغلوبین</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تم الإبلاغ عن الآثار الجانبیة الإضافیة التالیة المرتبطة بالعلاج بریفوليد في الأطفال (من عمر 1 إلى 17 سنة) مع</strong><strong> </strong><strong>&nbsp;</strong><strong>ITP</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>إذا أصبحت ھذه الآثار الجانبیة شدیدة ، فیرجى إخبار طبیبك أو الصیدلي أو الممرض</u><u>.</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>الآثار الجانبیة الشَّائعة جدًا</strong></p><p dir="RTL">قد تُؤثر ھذه التَّأثیرات على <strong>أكثر من طفل واحد من بین كل</strong> 10 أطفال:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب الحلق، سیلان الأنف، احتقان الأنف، العطس.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالأنف، والجیوب الأنفیة، والحلق، والممرات الھوائیة العلویة، نزلة البرد (عدوى الجھاز التنَّفسي العلوي(</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسِھال.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كحة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; درجة حرارة مرتفعة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثیان</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الشائعة</strong></p><p dir="RTL">قد تُؤثر ھذه التأَّثیرات على ما <strong>یصل إلى طفل واحد من بین كل</strong> <strong>10</strong> أطفال:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم (الأرق)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالأسنان</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الأنف والحنجرة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة ، سیلان أو أنف مسدود</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب الحلق وسیلان الأنف واحتقان الأنف والعطس</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الفم بما في ذلك جفاف الفم ، التھاب الفم ، اللسان الحساس ، نزیف اللثة ، الفم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة المعدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تم الإبلاغ عن الآثار الجانبیة التالیة لتكون مرتبطة مع العلاج بریفوليد بالمزیج مع الانترفیرون والریبافیرین في</strong><strong> </strong><strong>الأشخاص المصابین بالتھاب الكبد الوبائي &quot;سي&quot;</strong></p><p dir="RTL"><strong>الآثار الجانبیة الشَّائعة جدًا</strong></p><p dir="RTL">قد تُؤثر ھذه التَّأثیرات على أكثر <strong>من شخص واحد من بین كل 10</strong> أشخاص:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشھیة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعیاء (غثیان)، الإسھال.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام بالعضلات، وضعف بالعضلات</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الطاقة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط غیر طبیعي للشعر</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بمرض شبیھ بالأنفلونزا</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الیدین أو القدمین</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتعاش.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الشائعة جدًا التي قد تظھر في اختبارات الدَّم</strong><strong>:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلایا الدَّم الحمراء (فقر الدمَّ).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الشائعة</strong></p><p dir="RTL">قد تُؤثر ھذه التَّأثیرات على <strong>ما یصل إلى شخص واحد من بین كل 10</strong> أشخاص:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجھاز البولي.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب الممرات الأنفیة، والحلق والفم، أعراض شبیھة بالأنفلونزا، جفاف الفم، تقرح أو التھاب الفم، ألم الأسنان.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النوَّم، والنعاس غیر الطبیعي، والارتباك، والاكتئاب، والقلق، والھِیاج.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة، ومشاكل بالانتباه والذاكرة، تغییر في المزاج</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو تنمیل بالیدین أو القدمین.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرارة ، صداع</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالعین، بما في ذلك: إعتام عدسة العین (المیاه البیضاء)، جفاف العین، تكوّن رواسب صفراء صغیرة في</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شبكیة العین، اصفرار بیاض العین.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث نزیف في الشبكیة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالدوران (الدوار)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات سریعة أو غیر منتظمة (خفقان) ، وضیق في التنفس</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال المصحوب ببلغم. سیلان الأنف ، والأنفلونزا ، والتھاب البرد ، والتھاب الحلق والانزعاج عند البلع.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالجھاز الھضمي، من ضمنھا: الإعیاء (القيء)، ألم بالمعدة، عسر الھضم، الإمساك، انتفاخ المعدة، اضطرابات التذَّوق، التھاب المعدة، بواسیر، وتھیج القناة الھضمیة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالأسنان</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالكبد، بما في ذلك الجلطة الدمَّویة، ورم بالكبد (انظر &quot;مشاكل الكبد&quot; أعلاه في القسم: 4)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغیرات جلدیة، بما في ذلك: الطفح الجلدي، وجفاف الجلد، والإكزیما، واحمرار الجلد، والحكة، والتعَّرق المفرط، ومواضع نمو غیر معتادة بالجلد.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل، آلام الظھر، آلام العظام، ألم في الیدین أو القدمین، تشنجات عضلیة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ھیاج، وشعور عام بالتوَّعك، وألم وشعور بالانزعاج بالصدر.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى في الأنف ، الجیوب الأنفیة ، الحلق والمجرى الھوائي العلوي ، نزلات البرد (عدوى الجھاز التنفسي العلوي)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب والقلق ومشاكل النوم والعصبیة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الشَّائعة التي قد تظھر في اختبارات</strong><strong> </strong><strong>الدَّم</strong><strong>:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى السكر (الجلوكوز) في الدمَّ.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلایا الدمَّ البیضاء.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض بروتینات الدمَّ.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع البیلیروبین (مادة ینتجھا الكبد).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغیرُّات فى الإنزیمات المتحكمة في تجلط الدمَّ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة غیر الشائعة</strong></p><p dir="RTL">قد تُؤثر ھذه التَّأثیرات على <strong>ما یصل إلى شخص واحد من بین كل 100</strong> شخص:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عند التبَّول.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في ضربات القلب (إطالة (QT</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفلونزا المعدة (التھاب المعدة والأمعاء)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یتغیر لون الجلد بما في ذلك التغیر في اللون ، التقشیر ، الاحمرار ، الحكة والتعرق.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار بیاض العینین أو الجلد (الیرقان)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الأوعیة الدمویة والنزیف في المريء (المريء)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي ، كدمات في موقع الحقن</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلایا الدم الحمراء (فقر الدم) الناجم عن التدمیر المفرط للدم الأحمرخلایا (فقر الدم الانحلالي)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك ، والھیجان</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة الكبد بسبب الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة التاَّلیة تم الإبلاغ عن ارتباطھا بالعلاج بعقار ریفولاد في المرضى المصابین بفقر الدَّم غیر التنسجي</strong><strong> </strong><strong>الشَّدید</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبیة الشَّائعة جدًا</strong></p><p dir="RTL">قد تُؤثر ھذه التَّأثیرات <strong>على أكثر من شخص واحد من بین كل</strong> 10 أشخاص.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالأنف والحَلْق.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسِْھال.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثیان.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالأطراف (الذراعین، والساقین، والیدین، والقدمین).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعَّب الشَّدید (الإرھاق).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعریرة برد</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في العیون</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثور في الفم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع بطن</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات عضلیة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الشائعة جدًا التي قد تظهر في اختبارات الدم</strong><strong>:</strong></p><p dir="RTL">&middot;تغیراتٍ غیر طبیعیة بالخلایا الموجودة لدیك بالنخاع العظمي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الشائعة</strong></p><p dir="RTL">قد تُؤثر ھذه التَّأثیرات على <strong>ما یصل إلى شخص واحد من بین كل 10</strong> أشخاص.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالبرد.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتوعك.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالعین، بما في ذلك: رؤیة ضبابیة إعتام عدسة العین (المیاه البیضاء)، بقع أو رواسب في العین (عوائم بالجسم الزجاجي للعین)، جفاف العین، حكة بالعین، اصفرار بیاض العین أو اصفرار الجلد.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزیف الأنف.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزیف اللثة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالجھاز الھضمي من ضمنھا: الإعیاء (القيء)، وتغیُّر بالشھیة (زیادة أو نقص الشھیة)، ألم/ شعور بالانزعاج بالمعدة، وانتفاخ المعدة، وإخراج ریح، وتغیر لون البراز.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الجلد بما في ذلك: ظھور بقعة حمراء أو أرجوانیة صغیرة ناجمة عن نزیف داخل الجلد [حبَرَات (نقاط نزفیة دقیقة)]، طفح جلدي، وحكة، وإصابة جلدیة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الظھر.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعظام.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف (وھن).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم بالأطراف السفلیة، نتیجة تراكُم السوائل.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بول ذو لون غیر طبیعي.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب بإمداد الدمَّ إلى الطحال (احْتِشَاء الطحال).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سیلان الأنف</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الشَّائعة التي قد تظھر في اختبارات الدَّم</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة في مستوى الإنزیمات بسبب انحلال العضلات (فسْفوُكیناز الكْریاتین).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تراكم الحدید في الجسم (التحَّمیل المفرط بالحدید).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى السكر (نقص السكر بالدمَّ).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع البیلیروبین (مادة ینتجھا الكبد).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة مستویات إنزیمات الكبد (الأسبارتات أمینوتراز (AST))</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستویات خلایا الدم البیضاء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة ذات معدل التكرار غیر المعروف</strong></p><p dir="RTL">لا یمكن تقدیر معدل التكرار من واقع البیانات المتاحة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغیر لون الجلد</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سواد الجلد</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد والعینین والحنان حول الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبیة</strong></p><p dir="RTL">إذا أصُبت بأیة آثار جانبیة، فتحدثَّ إلى طبیبك أو الصیدلي أو الممرض(ة) الخاص(ة) بك. ویشمل ذلك أیة آثار جانبیة مُحتمَلة، غیر المُدرجة في ھذه النَّشرة. یمكنك أیضًا الإبلاغ عن الآثار الجانبیة بشكل مباشر. بإبلاغك عن الآثار الجانبیة، یمكنك المساعدة في توفیر المزید من المعلومات حول أمان استخدام ھذا الدوَّاء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحُفظ ھذا الدوَّاء بعیداً عن رؤیة ومتناول الأطفال.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل ھذا الدوَّاء بعد تاریخ انتھاء الصلاحیة المدون على العبوة الكرتونیة والشریط.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدویة عن طریق إلقائھا في میاه الصَّرف أو مع المخلفات المنزلیة. استشر الصیدلي الخاص بك عن كیفیة التخَّلص من الأدویة التي لم تعَدُ تستخدمھا. سوف تُساعد ھذه الإجراءات في حمایة البیئة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یُحفظ في درجة حرارة أقل من 30 درجة مئویة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">المادة الفعالة في عقار ريڤوليد هي الترومبوباج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>25 </strong><strong>مجم أقراص مغلفة</strong></p><p dir="RTL">يحتوي كل قرص مغلف على الترومبوباج أولامين بما يُعادِل 25 مجم من الترومبوباج.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>50 </strong><strong>مجم أقراص مغلفة</strong></p><p dir="RTL">يحتوي كل قرص مغلف على الترومبوباج أولامين بما يُعادِل 50 مجم من الترومبوباج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: هيبروميلوز، ماكروجول 400، ستيرات الماغنسيوم، مانيتول (E421)، سليلوز دقيق التَّبلور، بوفيدون، جليكولات نشا الصوديوم، ثاني أكسيد التيتانيوم (E171).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي أقراص عقار ريڤوليد 25 مجم المغلَّفة أيضًا على بوليسوربات 80 (E433).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي أقراص عقار ريڤوليد 50 مجم المغلَّفة أيضًا على أكسيد الحديد الأحمر (E172) وأكسيد الحديد الأصفر (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تكون أقراص عقار ريڤوليد 25 مجم مغلفة، مستديرة، ثنائية التَّحدب، بيضاء، محفور على أحد جانبيها &quot;GS NX3&quot; و &quot;25&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تكون أقراص عقار ريڤوليد 50 مجم مغلفة، مستديرة، ثنائية التَّحدب، ذات لون بني، محفور على أحد جانبيها &quot;GS UFU&quot;و &quot;50&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوافر الأقراص في شرائط ألومنيوم في عبوة كرتونية تحتوي على 14 أو 28 قرصًا مغلفًا، وعبوات متعددة تحتوي على 84 قرصًا مغلفًا (3 عبوات بكلٍّ منها 28).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في دولتك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌د.	تم آخر اعتماد لهذه النَّشرة من قبل منظمة الأدوية السويسرية  في 12/2023

هـ.  للإبلاغ عن الأعراض الجانبية : 
•	المملكة العربية السعودية

   - المركز الوطني للتيقظ والسلامة الدوائية (NPC)
•	مركز اتصال الهيئة السعودية للغذاء والدواء: 19999
•	البريد الالكتروني: npc.drug@sfda.gov.sa
•	الموقع الالكتروني: https://ade.sfda.gov.sa

-	شركة نوفارتس - السعودية - قسم سلامة المرضى:
•	الهاتف المجاني: 8001240078
•	الهاتف:  +966112658100
•	الفاكس: +966112658107
•	البريد الالكتروني: adverse.events@novartis.com

و.  للإبلاغ عن أي شكوى:  complaints.ksa@novartis.com
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Revolade 25 mg film-coated tablets
Revolade 50 mg film-coated tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Revolade 25 mg film-coated tablets
Each film-coated tablet contains eltrombopag olamine equivalent to 25 mg eltrombopag.

Revolade 50 mg film-coated tablets
Each film-coated tablet contains eltrombopag olamine equivalent to 50 mg eltrombopag.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.


Revolade 25 mg film-coated tablets
White, round, biconvex film-coated tablet (approximately 10.3 mm in diameter) debossed with ‘GS NX3’ and ‘25’ on one side.

Revolade 50 mg film-coated tablets
Brown, round, biconvex film-coated tablet (approximately 10.3 mm in diameter) debossed with ‘GS UFU’ and ‘50’ on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Revolade is used for the following indications:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the treatment of adult patients with immune (idiopathic) thrombocytopenic purpura (ITP) lasting at least 6 months from diagnosis who have not responded sufficiently to other treatment options (e.g. corticosteroids, immunoglobulins or splenectomy) when there is an increased risk of bleeding due to pronounced thrombocytopenia.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the treatment of paediatric patients (aged 1 year and older) with immune (idiopathic) thrombocytopenic purpura (ITP) lasting at least 6 months from diagnosis and a significant tendency to bleed who have not responded to an established treatment (e.g. IVIG, corticosteroids) and for whom splenectomy is not a treatment option.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the treatment of thrombocytopenia in adult patients aged 18 years and older with chronic hepatitis C virus (HCV) infection, where the degree of thrombocytopenia prevents the initiation of interferon-based therapy and/or the ability to optimally maintain it.</p><p>Revolade has not been tested in combination with HCV protease inhibitors (boceprevir, telaprevir).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the treatment of cytopenias in adult patients with acquired severe aplastic anaemia (SAA) who are either treatment-refractory or who have undergone considerable prior therapy and who are not eligible for a haematopoietic stem cell transplant at the time of indication.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the first-line treatment of acquired severe aplastic anaemia (SAA) in combination with standard immunosuppressive therapy in adult and paediatric patients aged 2 years and over who are unsuitable for haematopoietic stem cell transplantation at the time of diagnosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Revolade dosage regimens must be individualised based on the patient&rsquo;s platelet count.</p><p>The lowest effective dosage regimen to maintain platelet counts should always be used, as clinically indicated.</p><p>After any Revolade dose adjustment platelet counts should be monitored at least weekly for two to three weeks. Any new dose adjustment can only be considered after waiting at least two weeks, once the effect of the previous adjustment on the patient&rsquo;s platelet count has become apparent.</p><p>The tablets and suspension are taken orally.</p><p>&nbsp;</p><p>Revolade should be taken at least two hours before or at least four hours after products such as antacids, dairy products or mineral supplements containing polyvalent cations (e.g. aluminium, calcium, iron, magnesium, selenium and zinc). Revolade may be taken with food that does not contain calcium or that only contains a small amount of calcium (&lt;50 mg) (see &ldquo;Interactions&rdquo; and &ldquo;Pharmacokinetics&rdquo;).</p><p>&nbsp;</p><p><em><u>Immune (idiopathic) thrombocytopenic purpura (ITP)</u></em></p><p><em>&nbsp;</em></p><p>To reduce the risk of bleeding, after the start of treatment adjust the dose to achieve and maintain a platelet count of &sup3;50,000/ml.</p><p>Dose adjustments are based on the platelet count response.</p><p>A dose of 75 mg once daily should not be exceeded. Revolade should only be used in patients with an increased bleeding risk due to pronounced thrombocytopenia. The platelet count should only be increased to a value required to avoid bleeding events and not to the physiological range.</p><p>Patients should be clinically assessed periodically and a decision taken by the treating physician on a case-by-case basis about whether to continue the treatment. Recurrence of thrombocytopenia is possible following discontinuation of treatment.</p><p>The treatment of ITP with Revolade must be stopped if, after four weeks of therapy with 75 mg/day, platelet counts do not increase sufficiently.</p><p>&nbsp;</p><p>Adults</p><p>&nbsp;</p><p>Starting dose</p><p>The recommended starting dose of Revolade in ITP is 50&nbsp;mg once daily. For patients of Asian descent and for patients with hepatic impairment the starting dose should be reduced to 25&nbsp;mg (see &ldquo;Special patient populations&rdquo;).</p><p>&nbsp;</p><p>Monitoring and dose adjustment</p><p>The standard dose adjustment is by 25&nbsp;mg increments/decrements. However, in some ITP patients a combination of different tablet strengths on different days may be required.</p><p>&nbsp;</p><p>Table <!--[if supportFields]><span
style='mso-bookmark:_Ref493608580'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref493608580'><span lang=EN-GB style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;line-height:150%;mso-fareast-language:EN-US;
font-weight:normal'><span style='mso-spacerun:yes'> </span>SEQ Tabelle \*
ARABIC <span style='mso-element:field-separator'></span></span></span><![endif]-->1<!--[if supportFields]><span
style='mso-bookmark:_Ref493608580'></span><span style='mso-element:field-end'></span><![endif]-->: Dose adjustment of Revolade in adult ITP patients</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Platelet count</p></td><td><p>Dose adjustment</p></td></tr><tr><td><p>&lt;50,000/ml after a minimum of 2&nbsp;weeks&rsquo; treatment</p></td><td><p>Increase dose by 25&nbsp;mg.</p></td></tr><tr><td><p>&sup3;200,000/ml to &le;400,000/ml</p></td><td><p>Reduce dose by 25&nbsp;mg.</p><p>In patients on 25&nbsp;mg Revolade a dose of 12.5&nbsp;mg should be considered.</p></td></tr><tr><td><p>&gt;400,000/ml</p></td><td><p>Stop Revolade.</p><p>At a platelet count of &lt;150,000/ml reinitiate therapy at a reduced daily dose.</p><p>In patients on 25&nbsp;mg Revolade a dose of 12.5&nbsp;mg should be considered.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Paediatric patients</em></p><p>The recommended starting dose of Revolade in ITP is based on body weight (BW) and ethnicity.</p><p>The dose adjustment should be carried out taking into consideration the clinical necessity and depending on any planned measures (e.g. neurosurgical procedures). The target platelet count is &gt;50&lsquo;000/&micro;l and should be titrated as clinically necessary.</p><p>Paediatric patients aged 6 to 17&nbsp;years</p><p>Starting dose</p><p>Non-Asian descent, BW &gt;27&nbsp;kg: 50&nbsp;mg once daily</p><p>Non-Asian descent, BW &lt;27&nbsp;kg: 37.5&nbsp;mg once daily</p><p>Asian descent, no weight data: 25&nbsp;mg once daily</p><p>For patients with hepatic impairment the starting dose should be reduced to 25&nbsp;mg (see &ldquo;Special patient populations&rdquo;).</p><p>&nbsp;</p><p>Monitoring and dose adjustment</p><p>The standard dose adjustment is by 25&nbsp;mg increments/decrements. However, in some ITP patients a combination of different tablet strengths on different days may be required.</p><p>Table&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Ref469921015'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref469921015'><span lang=EN-GB style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US;font-weight:normal'> SEQ
Tabelle \* ARABIC <span style='mso-element:field-separator'></span></span></span><![endif]-->2<!--[if supportFields]><span
style='mso-bookmark:_Ref469921015'></span><span style='mso-element:field-end'></span><![endif]-->: Dose adjustment of Revolade in paediatric ITP patients aged 6&nbsp;to&nbsp;17&nbsp;years</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Platelet count</p></td><td><p>Dose adjustment</p></td></tr><tr><td><p>&lt;50,000/ml after a minimum of 2&nbsp;weeks&rsquo; treatment</p><p>&nbsp;</p></td><td><p>Increase daily dose by 25&nbsp;mg, up to a maximum dose of 75&nbsp;mg/day.</p><p>&nbsp;</p></td></tr><tr><td><p>&sup3;200,000/ml to &le;400,000/ml</p></td><td><p>Reduce the daily dose by 25&nbsp;mg.</p><p>In patients on 25&nbsp;mg Revolade a dose of 12.5&nbsp;mg should be considered.</p></td></tr><tr><td><p>&gt;400,000/ml</p></td><td><p>Stop Revolade.</p><p>At a platelet count of &lt;150,000/ml reinitiate therapy at a reduced daily dose.</p><p>In patients on 25&nbsp;mg Revolade a dose of 12.5&nbsp;mg should be considered.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><br /><em><u>Chronic hepatitis&nbsp;C (HCV) associated thrombocytopenia</u></em></p><p><em><u>&nbsp;</u></em></p><p>When Revolade is given in combination with peginterferon-based antiviral therapy regimens, the dosage instructions in the prescribing information of all co-administered medicinal products should be observed.</p><p>Inducing a platelet count that would allow peginterferon-based anti-HCV therapy should begin with the lowest possible Revolade dose and the QT interval should be monitored via ECG (see &ldquo;Warnings/precautions&rdquo;). For a daily dose of less than 25&nbsp;mg Revolade consideration of a 25&nbsp;mg dose every other day is recommended.</p><p>During antiviral therapy the therapeutic target should be to maintain the platelet count at a level that keeps the risk of bleeding and thrombosis low but is also compatible with full-dose peginterferon therapy (<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB;font-weight:normal;mso-no-proof:no'><span
style='mso-element:field-begin'></span> REF _Ref493608312 \h<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 6<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003400390033003600300038003300310032000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-ansi-language:EN-GB;font-weight:normal;mso-no-proof:no'><span
style='mso-element:field-end'></span></span><![endif]-->).</p><p>In clinical studies platelet counts generally increased within one week of starting treatment with Revolade.</p><p>Revolade should only be used in patients with an increased bleeding risk due to pronounced thrombocytopenia. The platelet count should only be increased to a value required to avoid bleeding events and not to the physiological range.</p><p>Starting dose</p><p>Initiate Revolade therapy in HCV patients at a dose of 25&nbsp;mg once daily.</p><p>Monitoring and dose adjustment</p><p>Dose adjustments are based on the platelet count response. Adjust the Revolade dose in 25&nbsp;mg increments at two‑week intervals until the platelet count required to initiate antiviral therapy is achieved.</p><p>Platelet count stabilisation during antiviral therapy:</p><p>To avoid a peginterferon dose reduction during antiviral therapy, the Revolade dose must also be adjusted continuously during antiviral therapy while monitoring the platelet count. It is recommended that complete blood counts are performed every two weeks. Platelet counts should be monitored weekly in the event of unstable platelet counts during antiviral therapy.</p><p>The Revolade dose should be adjusted as per Table&nbsp;6. The target platelet count range is between 75,000 and 100,000/&mu;l.</p><p>A dose of 100&nbsp;mg once daily should not be exceeded.</p><p>Table <!--[if supportFields]><span
style='mso-bookmark:_Ref493608312'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref493608312'><span lang=EN-GB style='mso-ansi-language:
EN-GB;font-weight:normal;mso-no-proof:no'><span
style='mso-spacerun:yes'> </span>SEQ Tabelle \* ARABIC <span style='mso-element:
field-separator'></span></span></span><![endif]-->6<!--[if supportFields]><span
style='mso-bookmark:_Ref493608312'></span><span style='mso-element:field-end'></span><![endif]-->: Dose adjustment of Revolade in HCV patients during antiviral therapy</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Platelet count</p></td><td><p>Dose adjustment at 2-week intervals</p></td></tr><tr><td><p>&lt;50,000/ml</p></td><td><p>Increase daily dose by 25&nbsp;mg up to a maximum dose of 100&nbsp;mg</p></td></tr><tr><td><p>&ge;50,000/&mu;l to &le;200,000/&mu;l</p></td><td><p>Administer the lowest effective Revolade dose necessary to avoid peginterferon dose reductions.</p></td></tr><tr><td><p>&gt;200,000/&mu;l to &le;400,000/&mu;l</p></td><td><p>Reduce the daily dose by 25&nbsp;mg. Wait 2&nbsp;weeks to assess the effects of this and adjust dose as necessary.</p><p>Platelet counts may fall upon initiation of antiviral therapy, so immediate Revolade dose reductions should be avoided.</p></td></tr><tr><td><p>&gt;400,000/&micro;l</p></td><td><p>Stop Revolade, increase the frequency of platelet monitoring to twice weekly.</p><p>Once the platelet count is &le;150,000/&micro;l, reinitiate therapy at a daily dose reduced by 25&nbsp;mg.</p><p>For patients on 25&nbsp;mg Revolade reduce to 12.5&nbsp;mg once daily.</p></td></tr></tbody></table><p>*For patients taking 25 mg Revolade/Promacta once daily a dose of 12.5 mg once daily, or alternatively a dose of 25 mg once every other day, should be considered.</p><p>Discontinuation of therapy</p><p>Revolade treatment should be terminated when antiviral therapy is discontinued. Excessive platelet count responses and increased liver values may require discontinuation of Revolade (see &ldquo;Warnings and precautions&rdquo;).</p><p>For patients with genotype 1/4/6 HCV discontinuation of Revolade should be considered independently of the decision on continuation of antiviral therapy if a patient has achieved no virological response (= reduction of HCV RNA in the blood by a factor of &gt;100) by week&nbsp;12. If HCV RNA is still detectable after 24&nbsp;weeks of therapy, Revolade should be discontinued (see &ldquo;Warnings and precautions&rdquo;).</p><p><strong>First-line therapy in severe aplastic anaemia</strong></p><p>Eltrombopag should be initiated concurrently with standard immunosuppressive therapy.</p><p>The initial dose of eltrombopag must not be exceeded.</p><p>Starting dose</p><p><em><u>Adults and adolescents aged 12&nbsp;to&nbsp;17&nbsp;years</u></em></p><p>The recommended starting dose of eltrombopag is 150&nbsp;mg once daily for 6&nbsp;months.</p><p>In adult and adolescent SAA patients of Asian descent (such as Chinese, Japanese, Taiwanese, Korean or Thai patients) eltrombopag should be initiated at a dose of 75&nbsp;mg once daily for 6&nbsp;months.</p><p><em>Paediatric patients aged 6&nbsp;to&nbsp;11&nbsp;years</em></p><p>The recommended starting dose of eltrombopag is 75&nbsp;mg once daily for 6&nbsp;months.</p><p>In paediatric SAA patients of Asian descent (such as Chinese, Japanese, Taiwanese, Korean or Thai patients) aged 6&nbsp;to&nbsp;11&nbsp;years eltrombopag should be initiated at a dose of 37.5&nbsp;mg once daily for 6&nbsp;months.</p><p>&nbsp;</p><p>Table <!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-weight:
bold'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>SEQ Tabelle \* ARABIC <span style='mso-element:
field-separator'></span></span><![endif]-->7<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]-->:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose of standard immunosuppressive therapy administered with eltrombopag in the pivotal study (see &ldquo;Properties/Actions&rdquo;)</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p><strong>Active substance</strong></p></td><td><p><strong>Dose administered in the pivotal study</strong></p></td></tr></thead><tbody><tr><td><p>h‑ATG</p></td><td><p>40&nbsp;mg/kg/day based on actual body weight, administered intravenously on days&nbsp;1&nbsp;to&nbsp;4 of the 6‑month treatment period.</p></td></tr><tr><td><p>Ciclosporin*</p><p>(therapeutic dose for 6&nbsp;months, from day&nbsp;1 to month&nbsp;6, adjusted to obtain a target therapeutic trough level between 200&nbsp;and&nbsp;400&nbsp;&mu;g/l)</p></td><td><p><u>Patients aged 12&nbsp;years and over:</u></p><p>3&nbsp;mg/kg based on actual body weight, orally every 12&nbsp;hours (total daily dose of 6&nbsp;mg/kg/day).</p><p>&nbsp;</p><p><em>Patients &gt;20&nbsp;years of age with a body mass index &gt;35 or patients aged 12&nbsp;to&nbsp;20&nbsp;years with a body mass index &gt;95<sup>th</sup> percentile:</em></p><p>3&nbsp;mg/kg based on adjusted body weight<sup>#</sup>, orally every 12&nbsp;hours (total daily dose of 6&nbsp;mg/kg/day).</p><p>&nbsp;</p><p><u>Paediatric patients aged 2&nbsp;to&nbsp;11&nbsp;years:</u></p><p>6&nbsp;mg/kg based on actual body weight, orally every 12&nbsp;hours (total daily dose of 12&nbsp;mg/kg/day).</p><p>&nbsp;</p><p><em>Patients aged 2&nbsp;to&nbsp;11&nbsp;years with a body mass index &gt;95<sup>th</sup> percentile:</em></p><p>6&nbsp;mg/kg based on adjusted body weight<sup>#</sup>, orally every 12&nbsp;hours (total daily dose of 12&nbsp;mg/kg/day).</p></td></tr><tr><td><p>Ciclosporin</p><p>(maintenance dose, from month&nbsp;6 to month&nbsp;24)</p></td><td><p><u>For patients who achieve a haematologic response at 6&nbsp;months:</u></p><p>2&nbsp;mg/kg/day orally at a fixed dose for an additional 18&nbsp;months.</p></td></tr><tr><td colspan="2"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>The ciclosporin dose may require adjustments to achieve the trough level recommended above when ciclosporin is administered as co-medication. See ciclosporin prescribing information.</em></p><p><em><sup># </sup></em><em>Calculated as the midpoint between the ideal body weight and actual body weight.</em></p></td></tr></tbody></table><p><em>Monitoring and dose adjustment</em></p><p>Clinical haematology and liver function tests should be performed regularly throughout therapy with eltrombopag and the dosage regimen of eltrombopag should be modified based on platelet counts as outlined in <!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;line-height:150%'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>REF _Ref14712302 \h <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 8<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000D0000005F00520065006600310034003700310032003300300032000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;line-height:150%'><span style='mso-element:
field-end'></span></span><![endif]-->.</p><p><!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;line-height:150%'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>REF _Ref14712324 \h <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 9<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000D0000005F00520065006600310034003700310032003300320034000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;line-height:150%'><span style='mso-element:
field-end'></span></span><![endif]--> summarises the recommendations for dose interruption, reduction or discontinuation of eltrombopag in the management of hepatic impairment and thrombosis/embolism events.</p><p>Table <!--[if supportFields]><span
style='mso-bookmark:_Ref14712302'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref14712302'><span lang=EN-GB style='mso-bidi-font-weight:
bold'><span style='mso-spacerun:yes'> </span>SEQ Tabelle \* ARABIC <span
style='mso-element:field-separator'></span></span></span><![endif]-->8<!--[if supportFields]><span
style='mso-bookmark:_Ref14712302'></span><span style='mso-element:field-end'></span><![endif]-->:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose adjustments of eltrombopag in first-line therapy in severe aplastic anaemia</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p><strong>Platelet count</strong></p></td><td><p><strong>Dose adjustment or response</strong></p></td></tr></thead><tbody><tr><td><p>&gt;200,000/&mu;l to &le;400,000/&mu;l</p></td><td><p>Decrease the daily dose by 25&nbsp;mg every 2&nbsp;weeks to the lowest dose that maintains a platelet count &ge;50,000/&mu;l.</p><p>In paediatric patients under 12&nbsp;years of age decrease the dose by 12.5&nbsp;mg*.</p></td></tr><tr><td><p>&gt;400,000/&mu;l</p></td><td><p>Discontinue eltrombopag for a week.</p><p>Once the platelet count is &le;200&lsquo;000/&micro;l, reinitiate therapy at a daily dose reduced by 25&nbsp;mg (or 12.5&nbsp;mg in paediatric patients under 12&nbsp;years of age)*.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Table <!--[if supportFields]><span
style='mso-bookmark:_Ref14712324'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref14712324'><span lang=EN-GB style='mso-bidi-font-weight:
bold'><span style='mso-spacerun:yes'> </span>SEQ Tabelle \* ARABIC <span
style='mso-element:field-separator'></span></span></span><![endif]-->9<!--[if supportFields]><span
style='mso-bookmark:_Ref14712324'></span><span style='mso-element:field-end'></span><![endif]-->:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended dose modification for hepatic impairment and thrombosis/embolism</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p><strong>Event</strong></p></td><td><p><strong>Recommendation</strong></p></td></tr></thead><tbody><tr><td><p>Hepatic impairment</p></td><td><p><u>Increase in ALT &gt;6&nbsp;x&nbsp;ULN:</u></p><p>Discontinue eltrombopag.</p><p>Once ALT is &lt;5&nbsp;x&nbsp;ULN, reinitiate treatment at the same dose.</p><p>&nbsp;</p><p><u>Increase in ALT &gt;6&nbsp;x&nbsp;ULN after reinitiating eltrombopag (not attributable to other inciting factors, e.g. serum sickness, sepsis or azole antifungals):</u></p><p>Monitor ALT at least every 3&nbsp;to&nbsp;4&nbsp;days.</p><p>&nbsp;</p><p><u>If ALT remains &gt;6&nbsp;x&nbsp;ULN on repeat blood tests:</u></p><p>Discontinue eltrombopag.</p><p>Once ALT is &lt;5&nbsp;x&nbsp;ULN, reinitiate treatment at a dose reduced by 25&nbsp;mg from the previous dose.</p><p>&nbsp;</p><p><u>If ALT increases to &gt;6&nbsp;x&nbsp;ULN on the reduced dose:</u></p><p>Reduce the daily dose of eltrombopag by 25&nbsp;mg until ALT is &lt;5&nbsp;x&nbsp;ULN.</p><p>&nbsp;</p><p>There are no data on dose modification due to hepatic impairment in paediatric patients. Dose modification proportional to that in adults (e.g. 12.5&nbsp;mg) should be considered based on clinical judgement.</p></td></tr><tr><td><p>Thrombosis/embolism</p></td><td><p><u>Deep vein thrombosis, pulmonary embolism, TIA or stroke, myocardial infarction at any time during eltrombopag treatment:</u></p><p>Discontinue eltrombopag but continue h‑ATG and ciclosporin. If the platelet level is &gt;50,000/&mu;l at the time of thrombosis, treatment with enoxaparin or another appropriate anticoagulant is recommended as clinically indicated until the platelet count decreases to &lt;20,000/&mu;l or a 3&nbsp;to&nbsp;6‑month course of standard anticoagulation therapy is completed.</p></td></tr></tbody></table><p><em>Discontinuation of therapy</em></p><p>The total duration of eltrombopag treatment is 6&nbsp;months. Excessive platelet count responses (as outlined in <!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;line-height:150%'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>REF _Ref14712302 \h <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 8<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000D0000005F00520065006600310034003700310032003300300032000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;line-height:150%'><span style='mso-element:
field-end'></span></span><![endif]-->) or certain adverse events (as outlined in <!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;line-height:150%'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>REF _Ref14712324 \h <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 9<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000D0000005F00520065006600310034003700310032003300320034000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;line-height:150%'><span style='mso-element:
field-end'></span></span><![endif]-->) also necessitate discontinuation of eltrombopag.</p><p>Refractory severe aplastic anaemia (SAA)</p><p><em>Starting dose</em></p><p>Initiate treatment with Revolade at a dose of 50&nbsp;mg once daily. For patients of Asian descent and for patients with hepatic impairment the starting dose should be reduced to 25&nbsp;mg (see &ldquo;Special patient populations&rdquo;). Treatment should not be initiated if patients have existing cytogenetic abnormalities affecting chromosome&nbsp;7.</p><p>&nbsp;</p><p><em>Monitoring and dose adjustment</em></p><p>Haematological response may take up to 16&nbsp;weeks after starting Revolade treatment and may require dose escalation. This involves increasing the Revolade dose in 25&nbsp;mg increments every 2&nbsp;weeks until the target platelet count of &ge;50,000/&micro;l is achieved. A dose of 150&nbsp;mg once daily should not be exceeded. Clinical/haematological parameters and liver values should be monitored regularly throughout therapy with Revolade. The dosage of Revolade should be adjusted based on platelet counts as shown in <!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;line-height:150%'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>REF _Ref493608490
\h<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->Table <!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003400390033003600300038003400390030000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;line-height:150%'><span style='mso-element:
field-end'></span></span><![endif]-->. Bone marrow examinations with aspirations for cytogenetics are recommended prior to initiation of Revolade therapy, 3&nbsp;months after treatment initiation and 6&nbsp;months after discontinuation. If new cytogenetic abnormalities are detected, it must be carefully reconsidered whether continuation of therapy is appropriate.</p><p>&nbsp;</p><p>Table 10: Dose adjustments of Revolade in patients with severe aplastic anaemia</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Platelet count</p></td><td><p>Dose adjustment</p></td></tr><tr><td><p>&lt;50,000/&micro;l following at least 2&nbsp;weeks of treatment</p></td><td><p>Increase daily dose by 25&nbsp;mg to a maximum dose of 150&nbsp;mg/day</p></td></tr><tr><td><p>&ge;100,000/&micro;l to &le;200,000/&micro;l at any point during treatment</p></td><td><p>Reduce the daily dose by 50&nbsp;mg. Wait two weeks to assess the effects of this and any subsequent dose adjustments.</p></td></tr><tr><td><p>&gt;200,000/&micro;l</p></td><td><p>Stop Revolade for at least one week.</p><p>At a platelet count of &lt;150&rsquo;000/&micro;l reinitiate therapy at a dose reduced by 50&nbsp;mg.</p></td></tr><tr><td><p>&gt;200,000/&micro;l after 2&nbsp;weeks of treatment at the lowest dosage of Revolade</p></td><td><p>Discontinue Revolade. Reinitiate therapy with 25&nbsp;mg or the next lower dose once the platelet count is &lt;50,000/&micro;l.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Tapering for trilineage (white blood cells, red blood cells and platelets) responders</em></p><p>&nbsp;</p><p>Once platelet count &gt;50,000/&micro;l, haemoglobin &gt;10&nbsp;g/dl in the absence of red blood cell (RBC) transfusion and absolute neutrophil count (ANC) &gt;1&nbsp;x&nbsp;10<sup>9</sup>/l for more than 8&nbsp;weeks, the Revolade dose should be reduced by 50%. If values remain stable after 8&nbsp;weeks at the reduced dose, treatment with Revolade must be discontinued and the blood count monitored. If platelet count drops to &lt;30,000/&micro;l, haemoglobin concentration to &lt;9&nbsp;g/dl or ANC to &lt;0.5&nbsp;x&nbsp;10<sup>9</sup>/l, Revolade may be reinitiated at the previous dose.</p><p>&nbsp;</p><p><em>Discontinuation of therapy</em></p><p>&nbsp;</p><p>If no haematological response has occurred after 16&nbsp;weeks of therapy with Revolade, therapy should be discontinued. If new cytogenetic abnormalities are detected, it must be carefully re-evaluated whether continuation of Revolade is appropriate (see &ldquo;Warnings and precautions&rdquo;). Excessive platelet count responses or hepatic impairment may also require discontinuation of Revolade therapy <em>(see &ldquo;Warnings and precautions&rdquo;)</em>.</p><p><strong><em>&nbsp;</em></strong></p><p>Special populations</p><p><em>Children and adolescents</em></p><p>Revolade is not recommended in children under one year of age with ITP lasting at least 6&nbsp;months due to a lack of sufficient data on safety and efficacy.</p><p>The safety and efficacy of eltrombopag in the treatment of children and adolescents with thrombocytopenia in the case of chronic HCV infection, refractory SAA and definitive immunosuppressive therapy-naive SAA who are younger than 2&nbsp;years of age have not been established..</p><p>No data are available in any indication on children and adolescents with renal or hepatic impairment. No therapy recommendations can be given.</p><p>&nbsp;</p><p><em>Elderly patients </em></p><p>There are limited data on the use of Revolade in patients aged 65&nbsp;years and over.</p><p>In the clinical ITP studies no overall clinically significant difference in the safety of eltrombopag was observed between patients aged 65&nbsp;years and above and younger patients.</p><p>For HCV patients, however, there is evidence of more frequent serious adverse events during treatment with Revolade in elderly patients, in particular gastrointestinal bleeding (see &ldquo;Warnings and precautions&rdquo;), with simultaneously limited efficacy in this subgroup (see &ldquo;Properties/Actions&rdquo;).</p><p>&nbsp;</p><p><em>Asian adult patients</em></p><p>In patients of Asian descent (such as Chinese, Japanese, Taiwanese or Korean patients), including those with hepatic impairment, Revolade should be initiated at a dose of 25&nbsp;mg once daily (see &ldquo;Pharmacokinetics in special populations&rdquo;).</p><p>Further dose adjustments should be based on the standard criteria (<!--[if supportFields]><span
lang=EN-GB style='font-size:11.0pt;line-height:150%;font-weight:normal;
mso-bidi-font-weight:bold;font-style:normal;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span> REF _Ref493608580 \h<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 1<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003400390033003600300038003500380030000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;line-height:150%;font-weight:normal;mso-bidi-font-weight:
bold;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-end'></span></span><![endif]-->, <!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;line-height:150%;font-weight:normal;mso-bidi-font-weight:
bold;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>REF _Ref469921015
\h<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->Table&nbsp;2<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003400360039003900320031003000310035000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;line-height:150%;font-weight:normal;mso-bidi-font-weight:
bold;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-end'></span></span><![endif]-->,<!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;line-height:150%;font-weight:normal;mso-bidi-font-weight:
bold;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-begin'></span> REF _Ref493608588 \h<span style='mso-spacerun:yes'> 
</span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 5<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003400390033003600300038003500380038000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;line-height:150%;font-weight:normal;mso-bidi-font-weight:
bold;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-end'></span></span><![endif]-->,<!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;line-height:150%;font-weight:normal;mso-bidi-font-weight:
bold;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-begin'></span> REF _Ref493608312 \h<span style='mso-spacerun:yes'> 
</span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 6<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003400390033003600300038003300310032000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;line-height:150%;font-weight:normal;mso-bidi-font-weight:
bold;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-end'></span></span><![endif]-->, Table&nbsp;10) and accompanied by continuous monitoring of the platelet count.</p><p>&nbsp;</p><p><em>Adult patients with renal impairment</em></p><p>Caution and close monitoring are required for the use of Revolade in adult patients with renal impairment due to the absence of clinical experience.</p><p>&nbsp;</p><p><em>Adult patients with hepatic impairment</em></p><p>Adult ITP patients with liver cirrhosis should use Revolade with caution and should be closely monitored. An interval of at least three weeks must be observed before adjusting the dose (see &ldquo;Warnings and precautions&rdquo;). For patients with a Child‑Pugh score &ge;5 the starting dose should be reduced to 25&nbsp;mg Revolade daily.</p><p>Adult patients with chronic HCV infection and hepatic impairment and refractory severe aplastic anaemia patients with hepatic impairment should be administered the standard starting dose of 25&nbsp;mg once daily. Any further dose adjustments should be undertaken subject to continuous monitoring of the platelet count in line with the standard criteria (<!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;mso-bidi-font-size:12.0pt;line-height:150%;font-weight:
normal;mso-bidi-font-weight:bold;font-style:normal;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span> REF _Ref493608580 \h<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 1<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003400390033003600300038003500380030000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;mso-bidi-font-size:12.0pt;line-height:150%;font-weight:
normal;mso-bidi-font-weight:bold;font-style:normal;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span><![endif]-->, <!--[if supportFields]><span lang=EN-GB style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;line-height:150%;font-weight:normal;mso-bidi-font-weight:
bold;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>REF _Ref469921015
\h<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->Table&nbsp;2<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003400360039003900320031003000310035000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;mso-bidi-font-size:12.0pt;line-height:150%;font-weight:
normal;mso-bidi-font-weight:bold;font-style:normal;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span><![endif]-->, <!--[if supportFields]><span lang=EN-GB style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;line-height:150%;font-weight:normal;mso-bidi-font-weight:
bold;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>REF _Ref493608588
\h<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->Table 5<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003400390033003600300038003500380038000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;mso-bidi-font-size:12.0pt;line-height:150%;font-weight:
normal;mso-bidi-font-weight:bold;font-style:normal;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span><![endif]-->, <!--[if supportFields]><span lang=EN-GB style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;line-height:150%;font-weight:normal;mso-bidi-font-weight:
bold;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>REF _Ref493608312
\h<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->Table 6<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003400390033003600300038003300310032000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;mso-bidi-font-size:12.0pt;line-height:150%;font-weight:
normal;mso-bidi-font-weight:bold;font-style:normal;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span><![endif]-->, <!--[if supportFields]><span lang=EN-GB style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;line-height:150%;font-weight:normal;mso-bidi-font-weight:
bold;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>REF _Ref493608490
\h<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->Table <!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003400390033003600300038003400390030000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;mso-bidi-font-size:12.0pt;line-height:150%;font-weight:
normal;mso-bidi-font-weight:bold;font-style:normal;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span><![endif]-->) (see &ldquo;Pharmacokinetics in special patient populations&rdquo; under &ldquo;Pharmacokinetics&rdquo;). Patients with a Child‑Pugh score &gt;9 were not investigated in the studies on HCV, ITP and SAA patients.</p><p>In a clinical study on definitive immunosuppressive therapy-naive severe aplastic anaemia, patients with baseline AST/ALT &gt;5&nbsp;x&nbsp;ULN were ineligible to participate. The initial dose of eltrombopag in patients with hepatic impairment in the first-line setting should be determined as necessary based on clinical judgement, tolerability and close monitoring of liver function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance eltrombopag or to any of the ingredients of the medicinal product.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The efficacy and safety of eltrombopag have not been established for use in other thrombocytopenic conditions such as chemotherapy-induced thrombocytopenia or myelodysplastic syndrome (MDS).</p><p>In the SAA indication there is only limited safety data from one open-label study. Due to the higher exposure in this indication a higher frequency and/or greater severity of the adverse effects described below (particularly of hepatotoxicity and thromboembolic events) cannot be ruled out. This also applies to drug interactions (see &ldquo;Interactions&rdquo;).</p><p>This medicinal product contains less than 1&nbsp;mmol (23&nbsp;mg) of sodium per film-coated tablet, making it practically &ldquo;sodium-free&rdquo;.</p><p>&nbsp;</p><p><strong>Grade&nbsp;4 neutropenia (&lt;500/&micro;l) and blood count monitoring for paediatric ITP patients </strong></p><p>In two placebo-controlled studies (PETIT and PETIT2) with paediatric patients (between 1&nbsp;and&nbsp;17&nbsp;years of age) with ITP lasting at least 6&nbsp;months 3&nbsp;cases (2.8%) of grade&nbsp;4 neutropenia (&lt;500/&micro;l) were observed on eltrombopag and 0&nbsp;cases on placebo. There was one case of fungal pneumonia. Neutropenia of all grades occurred in 15.9% of patients on eltrombopag and 10.0% of patients on placebo. During treatment of paediatric patients with eltrombopag regular blood counts must be performed (as well as additional blood counts in the event of fever). Patients and their parents must be advised to seek immediate medical treatment in the event of a fever.</p><p>&nbsp;</p><p><strong>Cases of death in thrombocytopenic patients with hepatitis&nbsp;C</strong></p><p>In two controlled studies in thrombocytopenic patients with hepatitis&nbsp;C (ENABLE&nbsp;1 and ENABLE&nbsp;2) peginterferon-based antiviral therapy in patients with HCV genotype 1/4/6 infections and/or advanced liver damage (MELD (Model for End-Stage Liver Disease) score &ge;10, FibroScan fibrosis stage F3 or F4, albumin &lt;3.5&nbsp;g/dl) resulted in more frequently observed cases of death in patients treated with eltrombopag. Overall, 3% of patients in the eltrombopag group died compared to 2% in the placebo group. The causes of death were mainly hepatic decompensation and bleeding, including bleeding oesophageal varices.</p><p><em>&nbsp;</em></p><p><strong>Hepatic impairment and hepatotoxicity</strong></p><p>Eltrombopag inhibits UGT1A1 and OATP1B1, which may lead to indirect hyperbilirubinaemia.</p><p>Treatment with Revolade may lead to changes in hepatobiliary laboratory values, to severe hepatotoxicity and to potentially fatal liver damage.</p><p>Revolade should be used with caution in patients with hepatic disease. Monitoring of laboratory values is obligatory (see below).</p><p><em>Clinical data</em></p><p>In clinical studies with eltrombopag an increase in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and indirect bilirubin was observed. This occurred approximately three months after the start of treatment. The hepatic changes were reversible after discontinuation of eltrombopag.</p><p><em>ITP patients</em></p><p>In clinical studies in ITP lasting at least 6&nbsp;months this increase was mostly mild (grade&nbsp;1‑2), reversible and not accompanied by any clinically significant symptoms that would indicate hepatic impairment. In two placebo-controlled studies in adult patients with ITP lasting at least 6&nbsp;months from diagnosis an increase in ALT was reported in 5.7% of patients on eltrombopag and 4.0% of patients on placebo.</p><p>In the paediatric study PETIT2 increased ALT values &ge;3x&nbsp;ULN were reported on eltrombopag in 4&nbsp;of&nbsp;26&nbsp;patients in cohort&nbsp;2 (6‑11&nbsp;years of age; both in the randomised period) and in 1&nbsp;of&nbsp;14&nbsp;patients in cohort&nbsp;3 (1‑5&nbsp;years of age) compared to 0&nbsp;cases on placebo. No such cases were reported in cohort&nbsp;1 (12‑17&nbsp;years of age).</p><p>In the paediatric studies changes in hepatobiliary laboratory values (patients with events that fulfilled at least one criterion) occurred in 7.5% of patients on eltrombopag versus 2% of patients on placebo, with hepatobiliary events occurring in 6.5% and 0% of patients on eltrombopag and placebo, respectively.</p><p><em>SAA patients</em></p><p>In the open-label SAA study an increase in ALT was reported in 19% of patients on eltrombopag.</p><p>In a single-arm, open-label clinical study in definitive immunosuppressive therapy-naive SAA patients who received eltrombopag concurrently with h‑ATG and ciclosporin, ALT or AST &gt;3&nbsp;x&nbsp;ULN with total bilirubin &gt;1.5&nbsp;x&nbsp;ULN was reported in 40/92 patients. None of these increases resulted in discontinuation.</p><p><em>Dose adjustment</em></p><p>In patients with ITP, HCV and refractory SAA, serum ALT, AST and bilirubin should be determined prior to initiation of Revolade treatment, every two weeks during the dose adjustment phase and monthly following achievement of a stable dose. Direct and indirect bilirubin fractions should be determined in the case of elevated total bilirubin levels. In the event of abnormal liver values repeat the tests within 3&nbsp;to&nbsp;5&nbsp;days. If the abnormalities are confirmed, monitor serum liver values until the abnormalities resolve, stabilise or return to baseline levels. Discontinue Revolade if ALT levels increase to &ge;3x&nbsp;ULN in patients with normal liver function or to &ge;3x baseline (or to &gt;5x&nbsp;ULN, if this value is lower) in patients with elevations in liver values before treatment and this increase:&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is progressive or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; persists for 4&nbsp;weeks or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is accompanied by increased direct bilirubin or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is accompanied by clinical symptoms of liver damage or evidence of hepatic impairment.</p><p>Gilbert&rsquo;s syndrome should be ruled out before initiating treatment (see &ldquo;Pharmacokinetics&rdquo;).</p><p>In the first-line treatment of severe aplastic anaemia, ALT, AST and bilirubin should be measured prior to initiation of eltrombopag. During treatment increases in ALT levels should be managed as recommended in <!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;line-height:150%'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>REF _Ref14712324 \h <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 9<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000D0000005F00520065006600310034003700310032003300320034000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;line-height:150%'><span style='mso-element:
field-end'></span></span><![endif]-->.</p><p>&nbsp;</p><p><strong>Hepatic impairment and hepatic decompensation in thrombocytopenic patients with hepatitis&nbsp;C</strong></p><p>In two controlled clinical studies on thrombocytopenic patients with chronic HCV infection (ENABLE&nbsp;1 and ENABLE&nbsp;2) more frequent cases of hepatic decompensation (13% versus 7%) were observed on peginterferon-based antiviral therapy and concomitant treatment with eltrombopag versus placebo. These were associated with symptoms such as jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome and bleeding oesophageal varices, some of which were fatal.</p><p>In patients with advanced liver disease at baseline (albumin &lt;3.5&nbsp;g/dl, MELD score &ge;10 and/or FibroScan/elastography score F3 or F4) the risk of hepatic decompensation and of fatal incidents was increased. These at-risk patients must be closely monitored for signs associated with potential hepatic decompensation. The appropriate discontinuation criteria for Revolade (see &ldquo;Dosage/Administration&rdquo;) and for the antiviral medicinal products (in the respective prescribing information) must be observed.</p><p>&nbsp;</p><p><strong>Thrombotic/thromboembolic complications and portal vein thrombosis</strong></p><p>If platelet counts are above the normal range, there is a risk of thromboembolic complications. The platelet count should be closely monitored. The dose should be reduced or treatment discontinued if the platelet count exceeds the desired value.</p><p>In studies in ITP patients thromboembolic events (TEEs) such as deep vein thrombosis in the leg, pulmonary embolism, transient ischaemic attack, myocardial infarction, ischaemic stroke or suspected PRIND (prolonged reversible ischaemic neurological deficit) were observed in 3.8% of patients.</p><p>&nbsp;</p><p>Thromboembolic events were also observed at low and normal platelet counts. Use particular caution when administering Revolade to patients with known risk factors of thromboembolism (e.g. Factor V Leiden, ATIII deficiency, antiphospholipid syndrome).</p><p>&nbsp;</p><p>ITP patients with hepatic impairment (Child‑Pugh score &ge;5) and/or liver cirrhosis are at increased risk of portal vein thrombosis during therapy with eltrombopag. The expected benefit must be carefully assessed in relation to this risk in this at-risk population and Revolade must be used with increased caution in patients with hepatic impairment (see &ldquo;Dosage/Administration&rdquo; and &ldquo;Adverse effects&rdquo;).</p><p>Revolade is not indicated for the treatment of thrombocytopenia in patients with chronic liver disease for whom invasive procedures are planned. In a controlled study in this patient population (n&nbsp;=&nbsp;288) the risk of portal vein thrombosis/thrombotic events was increased in patients who were given 75&nbsp;mg eltrombopag once daily for 14&nbsp;days. In adult patients with chronic liver disease TEEs occurred in 4% of patients on eltrombopag (all in the portal vein system) and in 1% of patients on placebo (1&nbsp;TEE in the portal vein system, 1 myocardial infarction). In five of the patients treated with eltrombopag the TEE occurred within 14&nbsp;days of the end of eltrombopag therapy and at a platelet count of &gt;200,000/&micro;l.</p><p>&nbsp;</p><p>In two controlled studies in thrombocytopenic patients with hepatitis&nbsp;C (ENABLE&nbsp;1 and ENABLE&nbsp;2), during peginterferon-based antiviral therapy 3% of patients in the group co-administered eltrombopag suffered a TEE compared to 1% in the placebo group, with portal vein thrombosis occurring most frequently.</p><p>&nbsp;</p><p><strong>Gastrointestinal bleeding in thrombocytopenic patients with hepatitis&nbsp;C:</strong></p><p>During peginterferon-based antiviral therapy severe gastrointestinal bleeding, sometimes with a fatal outcome, was observed during treatment with eltrombopag; patients must be closely monitored for this.</p><p>&nbsp;</p><p><strong>Bleeding following discontinuation of eltrombopag </strong></p><p>Following discontinuation of eltrombopag in ITP and HCV platelet counts return to baseline levels within two weeks in the majority of patients, which increases the risk of bleeding and, in some cases, may lead to bleeding. Platelet counts must be monitored weekly for four weeks following discontinuation of Revolade.</p><p>&nbsp;</p><p><strong>Prolonged QT interval </strong></p><p>In two controlled clinical studies (ENABLE&nbsp;1 and ENABLE&nbsp;2) in thrombocytopenic patients with hepatitis&nbsp;C QT intervals above 500&nbsp;ms were observed more frequently with eltrombopag compared to placebo (13/955 vs 2/484). QT prolongation may result in an increased risk of ventricular arrhythmias (including torsade de pointes) and cardiac arrest.</p><p>The extent of the QT prolongation increases with the dose. In patients with severe aplastic anaemia clinically relevant QT prolongation cannot be ruled out due to the higher exposure compared to healthy subjects and patients with other indications (see &ldquo;Pharmacokinetics&rdquo;) and due to the large number of co-medications. Therefore, the lowest effective dose should be administered. ECG monitoring must be performed and the QT interval checked before the first Revolade dose and once steady state has been reached after 3‑4&nbsp;weeks as well as at the time of the first dose and after every dose increase. Close monitoring of relevant electrolytes is also indicated. In the event of QT prolongations the dose must be reduced or Revolade discontinued. Caution is required where there are also other risk factors for arrhythmia, i.e. electrolyte disturbances (such as hypokalaemia or hypomagnesaemia), congenital or acquired long QT syndrome, pronounced bradycardia, recent acute myocardial infarction or decompensated heart failure and in case of concomitant treatment with medicinal products that prolong the QT interval or are associated with atypical ventricular tachycardia. These include in particular certain antiarrhythmics (e.g. quinidine, disopyramide, amiodarone), certain antimicrobial agents (e.g. macrolides, quinolones, triazole antifungals), methadone, certain antihistamines, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and neuroleptics. Electrolyte imbalances such as hypokalaemia and hypomagnesaemia must be corrected prior to commencing treatment with Revolade.</p><p>&nbsp;</p><p><strong>Malignancies and tumour progression</strong></p><p>It cannot be ruled out that TPO receptor agonists may stimulate the progression of haematological malignancies (e.g. MDS or AML).&nbsp; Revolade is not indicated for the treatment of MDS-induced thrombocytopenia. In a randomised, double-blind, placebo-controlled study in adult patients with MDS, cases of progression of MDS to AML were observed more frequently on eltrombopag than on placebo (12% vs 6%). All-cause mortality was also slightly higher on eltrombopag than on placebo (32% vs 29%). This study was ended early due to these numerical disadvantages for eltrombopag and a lack of efficacy in increasing platelet counts.</p><p><strong>Cataracts</strong></p><p>Cataracts were observed in toxicology studies with eltrombopag in rodents (see &ldquo;Preclinical data&rdquo;).</p><p>In controlled studies in thrombocytopenic patients with HCV receiving interferon-based therapy (n&nbsp;=&nbsp;1439) incident cataracts or progression of pre-existing cataracts were reported in 8% of patients on eltrombopag versus 5% of patients on placebo.</p><p>In the two studies (PETIT1 and PETIT2) in paediatric patients with ITP cataracts were observed in 1.2% of all patients on eltrombopag (1&nbsp;cataract in the double-blind phase and 1&nbsp;cataract in the open-label phase of the study). Both patients had been previously treated with systemic corticosteroids.</p><p>Routine ophthalmological monitoring is recommended to exclude cataracts. Children and adolescents receiving eltrombopag therapy must undergo regular slit-lamp examinations.</p><p>&nbsp;</p><p><strong>Cytogenetic aberrations, MDS and AML in SAA patients</strong></p><p>Cytogenetic abnormalities may occur in SAA patients and are associated with a risk of progression to MDS or AML. It cannot reliably be estimated from the data whether eltrombopag additionally increased the risk of cytogenetic abnormalities in SAA patients. In the clinical phase&nbsp;II study with eltrombopag in SAA patients new cytogenetic abnormalities occurred in 8&nbsp;of&nbsp;43&nbsp;patients (5 of these patients exhibited the prognostically unfavourable monosomy&nbsp;7). The median time to onset of a cytogenetic abnormality was 2.9&nbsp;months.</p><p>In the clinical phase&nbsp;II study with eltrombopag in SAA patients MDS was diagnosed in 3&nbsp;of&nbsp;43&nbsp;patients. The median time from the start of eltrombopag treatment to diagnosis was 3&nbsp;months.</p><p>SAA patients refractory to immunosuppressive therapy or who have undergone considerable prior immunosuppressant treatment are advised to undergo bone marrow aspiration for cytogenetic analysis prior to initiating therapy with Revolade, after 3&nbsp;months of treatment and 6&nbsp;months following discontinuation.</p><p>Pre-existing MDS and hereditary forms of SAA should be ruled out prior to treatment with Revolade.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Higher exposure in SAA patients</strong></p><p>Pharmacokinetic data in 23 SAA patients indicate that the dose-normalised exposure was higher in these patients than in other indications. On the basis of these limited data an increased risk of rare severe adverse effects such as hepatotoxicity, cardiotoxicity, QT prolongation and hypersensitivity reactions cannot be ruled out.</p><p>&nbsp;</p><p>Interactions</p><p>Eltrombopag is a substrate of CYP1A2 and CYP2C8 and an inhibitor of CYP2C9 and CYP2C8 <em>in vitro</em>.</p><p><em>In vitro</em>, eltrombopag is an inhibitor of several UGT enzymes. Caution is therefore advised when medicinal products excreted by glucuronidation are combined.</p><p><em>In vitro</em> studies have demonstrated that eltrombopag is not a substrate of the organic anion transporter protein OATP1B1, but is an inhibitor of it.</p><p>Furthermore, eltrombopag is a BCRP (Breast Cancer Resistance Protein) substrate and inhibitor, but not a substrate for P‑glycoprotein. However, caution is advised in the case of co-medication with P‑gp substrates.</p><p>&nbsp;</p><p><strong>Influence of other medicinal products on eltrombopag pharmacokinetics</strong></p><p>&nbsp;</p><p><em>Ciclosporin (BCRP inhibitor)</em>:</p><p>The administration of a single eltrombopag dose of 50&nbsp;mg with 200&nbsp;mg ciclosporin reduced the C<sub>max</sub> and AUC<sub>(0-inf)</sub> of eltrombopag by 25% (90%&nbsp;CI: 15%, 35%) and 18% (90%&nbsp;CI: 8%, 28%), respectively. When administered with 600&nbsp;mg ciclosporin, the corresponding reduction was 39% (90%&nbsp;CI: 30%, 47%) and 24% (90%&nbsp;CI: 14%, 32%), respectively.</p><p>This decrease in exposure is not considered clinically significant. Eltrombopag dose adjustment is permitted during the course of treatment based on the patient&rsquo;s platelet count (see &ldquo;Dosage/Administration&rdquo;). The platelet count should be monitored at least once weekly for two to three weeks when eltrombopag is co-administered with ciclosporin. The eltrombopag dose may have to be increased based on the platelet count.</p><p><em>&nbsp;</em></p><p><em>Lopinavir/ritonavir:</em></p><p>In healthy volunteers the co-administration of a single dose of 100&nbsp;mg eltrombopag with repeat-dose LPV/RTV (400/100&nbsp;mg) twice daily resulted in a reduction in eltrombopag plasma AUC<sub>(0-inf)</sub> of 17% (90%&nbsp;CI: 6.6%, 26.6%). Platelet counts should be monitored at least once weekly for 2&nbsp;to&nbsp;3&nbsp;weeks at the start or end of lopinavir/ritonavir therapy.</p><p><em>&nbsp;</em></p><p><em>HCV protease inhibitors: </em></p><p>In healthy subjects co-administration of repeat doses of 800&nbsp;mg boceprevir every 8&nbsp;hours or 750&nbsp;mg telaprevir every 8&nbsp;hours with a single dose of 200&nbsp;mg eltrombopag did not alter plasma eltrombopag exposure to a clinically significant extent.</p><p>&nbsp;</p><p><em>CYP1A2 and CYP2C8 inhibitors and inducers</em></p><p>Eltrombopag is metabolised through multiple pathways, including CYP1A2, CYP2C8, UGT1A1 and UGT1A3. Medicinal products that induce or inhibit only one of these enzymes are unlikely to affect plasma eltrombopag concentrations to a clinically significant extent. However, medicinal products that affect several of these pathways simultaneously may reduce (e.g. rifampicin) or increase (e.g. fluvoxamine) eltrombopag concentrations.</p><p><em>&nbsp;</em></p><p><em>Cotrimoxazole:</em></p><p>As trimethoprim is a CYP2C8 inhibitor, an interaction between eltrombopag and cotrimoxazole cannot be ruled out. Caution is therefore advised when co-administering eltrombopag with cotrimoxazole.</p><p>&nbsp;</p><p><em>Polyvalent cations (chelation)</em></p><p>Eltrombopag chelates with polyvalent cations such as aluminium, calcium, iron, magnesium, selenium and zinc (see &ldquo;Pharmacokinetics&rdquo;). Administration of a single dose of 75&nbsp;mg eltrombopag with an antacid containing polyvalent cations (1524&nbsp;mg aluminium hydroxide and 1425&nbsp;mg magnesium carbonate) reduced eltrombopag C<sub>max</sub> and AUC<sub>(0-inf)</sub> by 70%. Eltrombopag should be administered at least two hours before or at least four hours after ingesting antacids, dairy products or mineral supplements containing polyvalent cations to avoid a significant reduction in eltrombopag absorption (see &ldquo;Dosage/Administration&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Statins:</em></p><p>When eltrombopag and rosuvastatin were co-administered, rosuvastatin exposure was increased. This might also apply to other statins. When statins and eltrombopag are co-administered, it is therefore recommended that the statin dose be reduced by 50% and the patient should be carefully monitored.</p><p>&nbsp;</p><p><em>HCV protease inhibitors:</em></p><p>Co-administration of a single dose of 200&nbsp;mg eltrombopag with 750&nbsp;mg telaprevir every 8&nbsp;hours did not alter telaprevir exposure in healthy subjects. However, these data can only be extrapolated to the situation in HCV patients to a limited extent. No information on the effect on boceprevir exposure is available.</p><p>&nbsp;</p><p><em>Lopinavir/ritonavir:</em></p><p>Plasma levels of lopinavir and ritonavir were unaffected by concomitant administration of eltrombopag (100&nbsp;mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Women of childbearing potential/Contraception in males and females:</strong></p><p>Revolade is not recommended in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>The effects of eltrombopag on human pregnancy are unknown. Animal studies have shown reproductive toxicity. The potential risk to humans is unknown (see &ldquo;Preclinical data&rdquo;). The use of Revolade during pregnancy is not recommended.Breast-feeding</p><p><em>&nbsp;</em></p><p>It is not known whether eltrombopag or its metabolites pass into human milk. Studies in rats indicate that eltrombopag is likely to be excreted in breast milk (see &ldquo;Preclinical data&rdquo;). It is therefore recommended to stop breast-feeding prior to the start of therapy.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>Fertility was not affected in male and female rats in the range of human therapeutic exposure. However, a risk to humans cannot be ruled out (see &ldquo;Preclinical data&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no studies to investigate the effects of eltrombopag on the ability to drive or to use machines. No detrimental effects on such activities are anticipated based on the pharmacology or adverse effect profile of this medicinal product. The clinical condition of the patient and the safety profile of eltrombopag should be borne in mind when assessing the patient&rsquo;s ability to perform tasks that require judgement and motor/cognitive skills.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse effects are stated below separately for the different indications. Please note that the occurrence of adverse effects observed in clinical studies in one indication only cannot be ruled out in the other indications. This applies in particular to the SAA indication as only limited study data are available in this case.</p><p>The most common severe adverse effects observed in adults in the ITP or HCV studies were hepatotoxicity and thromboembolic events. Adverse drug reactions are listed below by MedDRA classification and using the following frequency categories: very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000).</p><p>&nbsp;</p><p>Adult patients with ITP lasting at least 6 months</p><p>The following information is based on pooled data from 3 double-blind, placebo-controlled studies and 3 open-label, uncontrolled studies in the ITP indication in which a total of 763 adult patients were exposed to eltrombopag, with a median duration of exposure of 304 days (max. 898 days).</p><p>&nbsp;</p><p>(For safety in the paediatric population see below)</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Infections and infestations</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Influenza, pharyngitis, sinusitis, pneumonia, oropharyngeal herpes, tonsillitis.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</em></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rectosigmoid cancer.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Blood and lymphatic system disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia, thrombocytopenia, leukocytosis, eosinophilia, leukopenia.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased band neutrophil count, increased platelet count, increased haemoglobin, haemolytic anaemia, anisocytosis, myelocytosis, presence of myelocytes.</p><p>&nbsp;</p><p><em>Immune system disorders</em></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity reactions (e.g. facial swelling).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Metabolism and nutrition disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypokalaemia, hyperuricaemia.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight gain, hypocalcaemia, anorexia, gout, increased total protein, increased serum albumin, increased appetite, decreased serum albumin.</p><p>&nbsp;</p><p><em>Psychiatric disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insomnia (and other sleep disorders), anxiety, depression. Uncommon:&nbsp; Altered mood, apathy, feeling sad.</p><p>&nbsp;</p><p><em>Nervous system disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Headache (24%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, paraesthesia, migraine (including cases with aura), hypoaesthesia, somnolence.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dysgeusia, tremor, hemiparesis, balance disorder, dysaesthesia, peripheral neuropathy, speech difficulties.</p><p>&nbsp;</p><p><em>Eye disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cataract, blurred vision, conjunctival haemorrhage, eye pain, dry eye, reduced visual acuity.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased lacrimation, blepharitis, retinal haemorrhage, cortical cataract, astigmatism, retinal pigment epitheliopathy, keratoconjunctivitis sicca.</p><p>&nbsp;</p><p><em>Ear and labyrinth disorders</em></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Earache.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Cardiac disorders</em></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; myocardial&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infarction,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiovascular&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders, palpitations, sinus tachycardia, QT prolongation.</p><p>&nbsp;</p><p><em>Vascular disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension, haematoma, hot flush, thromboembolic events (such as deep vein thrombosis, pulmonary embolism), thrombotic microangiopathy with acute renal failure.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Superficial thrombophlebitis, cyanosis.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; epistaxis</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep apnoea, pulmonary infarction, nasal discomfort, oropharyngeal blistering, sinus disorder.</p><p><em>&nbsp;</em></p><p><em>Gastrointestinal disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea (13%), nausea (11%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting, upper abdominal discomfort, constipati</p><p>on, dyspepsia, abdominal pain, gingival bleeding, mouth haemorrhage, haemorrhoids, abdominal discomfort, flatulence.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth, discoloured faeces, glossodynia, frequent bowel movements, haematemesis, oral discomfort, abdominal rigidity.</p><p>&nbsp;</p><p><em>Hepatobiliary disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Increased ALT (11%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased AST, increased alkaline phosphatase, hyperbilirubinaemia, abnormal hepatic function.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug-induced liver injury, hepatitis, cholestasis, hepatic lesion. A lower frequency&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of simultaneous ALT and AST elevation has also been observed.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Skin and subcutaneous tissue disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, pruritus, alopecia, petechiae, hyperhidrosis, urticaria.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin haemorrhage, generalised pruritus, skin discolouration, erythema, skin exfoliation, dermatosis, melanosis, pigmentation disorders.</p><p>&nbsp;</p><p><em>Musculoskeletal and connective tissue disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Arthralgia (12%), back pain (11%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in extremities, myalgia, musculoskeletal pain (including musculoskeletal chest pain), muscle spasm, bone pain.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness, sensation of heaviness.</p><p>&nbsp;</p><p><em>Renal and urinary disorders</em></p><p>Common: Thrombotic microangiopathy with acute renal failure, leukocyturia.</p><p>&nbsp;</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proteinuria, increased serum creatinine, renal failure, increased urine protein/creatinine ratio, nocturia, increased blood urea, increased urine pH, lupus nephritis.</p><p>&nbsp;</p><p><em>General disorders and administration site conditions</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Fatigue (12%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, influenza-like illness, peripheral oedema, asthenia, pain, (non-cardiac) chest pain.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malaise, mucosal inflammation, night sweats, feeling jittery, ill-defined disorder, wound inflammation, foreign body sensation.</p><p>&nbsp;</p><p>Paediatric patients with ITP</p><p>The safety of eltrombopag was investigated in paediatric patients with previously treated ITP from the age of 1 year in two double-blind studies with a subsequent open-label phase (see &ldquo;Properties/Actions&rdquo;). A total of 171 children and adolescents were exposed to eltrombopag. The following data are from the randomised study phase; significant events from the open-label phase of both studies were also taken into consideration.</p><p>The most common adverse effects in this population were upper respiratory tract infections, abdominal pain and haematological changes.</p><p>&nbsp;</p><p><em>Infections and infestations</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Upper respiratory tract infections (26%), nasopharyngitis (16%)</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Opportunistic infections (e.g. fungal pneumonia), pneumonia, subcutaneous abscesses.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Blood and lymphatic system disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp; Anaemia (24%), lymphopenia (22%), neutropenia (16%). Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; grade 4 neutropenia (i.e. &lt;500/&micro;l).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Metabolism and nutrition disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite, vitamin D deficiency.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Eye disorders</em></p><p><em>&nbsp;</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cataract (taking into consideration both the double-blind and open-label phase of the studies).</p><p>&nbsp;</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Cough (14%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oropharyngeal pain, rhinorrhoea.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p><em>&nbsp;</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain (18%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, toothache.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Hepatobiliary disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased alanine aminotransferase to 3x ULN, increased aspartate aminotransferase, increased alkaline phosphatase, increased bilirubin.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>General disorders and administration site conditions</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia (18%).</p><p>&nbsp;</p><p>Eltrombopag in combination with peginterferon-/ribavirin-based antiviral treatment in adult patients with HCV infection</p><p>The following information is based on pooled data from two double-blind, placebo-controlled studies in which a total of 1,521 patients were exposed to eltrombopag.&nbsp; The duration of exposure was 1-365 days (median: 182 days).</p><p>&nbsp;</p><p><em>Infections and infestations</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection, nasopharyngitis, upper respiratory tract infection, influenza, bronchitis, oral herpes.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastroenteritis, pharyngitis.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malignant hepatic neoplasm.</p><p>&nbsp;</p><p><em>Blood and lymphatic system disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (31%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukopenia, neutropenia, lymphopenia, increased INR, prolonged activated partial thromboplastin time, haemolytic anaemia.</p><p>&nbsp;</p><p><em>Metabolism and nutrition disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite (14%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss, hyperglycaemia, decreased serum albumin.</p><p><em>&nbsp;</em></p><p><em>Psychiatric disorders</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression, anxiety, sleep disorder.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion, agitation.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Nervous system disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Headache (22%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Light-headedness, dizziness, impaired concentration, dysgeusia, lethargy, hepatic encephalopathy, amnesia, paraesthesia.</p><p>&nbsp;</p><p><em>Eye disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cataract, retinal exudates, dry eye. Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Scleral icterus, retinal haemorrhage.</p><p>&nbsp;</p><p><em>Cardiac disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged QT interval.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Vascular disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thromboembolic events (including portal vein thrombosis).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Cough (12%; sometimes productive).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea (including exertional dyspnoea), oropharyngeal pain.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Nausea (18%), diarrhoea (16%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting, abdominal pain, ascites, dyspepsia, dry mouth, constipation, toothache, stomatitis, gastro-oesophageal reflux, haemorrhoids, other abdominal symptoms.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastritis, aphthous stomatitis, oesophageal varices with haemorrhage, flatulence.</p><p>&nbsp;</p><p><em>Hepatobiliary disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperbilirubinaemia, drug-induced liver injury, jaundice.</p><p>&nbsp;</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic failure.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Pruritus (12%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, dry skin, eczema, pruritic rash, hyperhidrosis, erythema, generalised pruritus, alopecia.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin lesion.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Musculoskeletal and connective tissue disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Myalgia (11%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arthralgia, muscle spasms, back pain, pain in extremities, musculoskeletal pain, bone pain.</p><p>&nbsp;</p><p><em>Renal and urinary disorders</em></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dysuria.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>General disorders and administration site conditions</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia (26%), fatigue (25%), influenza-like illness (16%), asthenia (13%),</p><p>chills (12%).</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability, pain, malaise, non-cardiac chest pain, oedema. Uncommon: Night sweats, chest discomfort.</p><p>&nbsp;</p><p>&nbsp;</p><p>Definitive immunosuppressive therapy-naive SAA population</p><p>The safety of eltrombopag in combination with horse antithymocyte globulin (h-ATG) and ciclosporin in patients with severe aplastic anaemia who had not received prior definitive immunosuppressive therapy (i.e. ATG therapy, alemtuzumab or high-dose cyclophosphamide) was evaluated in a single- arm, sequential-cohort study (see &ldquo;Properties/Actions&rdquo;). A total of 154 patients were enrolled and 153 were treated in this study, of whom 92 patients were enrolled in the cohort in which eltrombopag, h-ATG and ciclosporin were initiated concurrently at the recommended dose and schedule (the study&rsquo;s cohort 3 regimen): eltrombopag up to 150 mg once daily on day 1 to month 6 (D1-M6) in combination with h-ATG on days 1 to 4 and ciclosporin for 6 months followed by low-dose ciclosporin (maintenance dose) for an additional 18 months in patients with a haematologic response at 6 months. The median duration of exposure to eltrombopag in this cohort was 183 days, with 83.7% of patients exposed for &gt;12 weeks. A summary of the safety profile is included under &ldquo;Warnings and precautions&rdquo;.</p><p>The only adverse drug reaction associated with eltrombopag reported in definitive immunosuppressive therapy-naive SAA patients not previously reported in the refractory SAA study population is skin discolouration, including hyperpigmentation (5.4%). In definitive immunosuppressive therapy-naive SAA patients increased blood bilirubin was reported more frequently (17.4%) than in the refractory SAA study population.</p><p>New or worsening liver function laboratory changes (CTCAE grade 3 and grade 4) in the eltrombopag D1-M6 cohort were 15.2% and 2.2% for AST, 26.4% and 4.3% for ALT and 12.1% and 1.1% for bilirubin, respectively.</p><p><em>Paediatric patients</em></p><p>The safety assessment of eltrombopag in paediatric patients aged 2 to 17 years is based on 37 patients enrolled in the single-arm, sequential-cohort study: 2 patients aged 2 to 5 years, 12 patients aged 6 to 11 years and 23 patients aged 12 to 17 years. The safety profile in paediatric patients was consistent with the safety profile observed in the overall population.</p><p><em>Cytogenetic abnormalities</em></p><p>In the single-arm study in patients with definitive immunosuppressive therapy-naive SAA, patients had bone marrow aspirates evaluated for cytogenetic abnormalities. In the entire study across all cohorts clonal cytogenetic evolution occurred in 15 of 153 (10%) patients. 7 patients exhibited loss of chromosome 7, 6 cases of which occurred within 6.1 months. 4 patients had chromosomal aberrations whose significance was unclear and 3 patients had a deletion of chromosome 13 &ndash; considered a good prognostic factor in aplastic anaemia &ndash; and 1 patient had a follow-up bone marrow examination after 5 years with features of dysplasia with hypercellularity, raising concern for the possible development of MDS. In the Revolade D1-M6 cohort a new cytogenetic change was reported in 7 patients, 4 cases of which were loss of chromosome 7 occurring within 6.1 months. It is unclear whether these findings are due to the underlying disease, the immunosuppressive therapy and/or treatment with eltrombopag.</p><p>&nbsp;</p><p>Refractory SAA study population</p><p>The safety of eltrombopag in patients with severe aplastic anaemia was studied in an open-label, uncontrolled study (n = 43) in which 11 and 7 patients were given eltrombopag for more than 6 and more than 12 months, respectively, with a maximum duration of 39 months. The median duration of study treatment was 3.6 months.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;<em>Psychiatric disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Insomnia (12%).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Nervous system disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Headache (21%), dizziness (14%).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Eye disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cataract.</p><p>&nbsp;</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Cough (23%), oropharyngeal pain (14%), rhinorrhoea (12%).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Nausea (33%), diarrhoea (21%), abdominal pain (12%).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Hepatobiliary disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp; Increased transaminases (12%). Common:&nbsp;&nbsp;&nbsp; Hyperbilirubinaemia.</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, exfoliative dermatitis, erythema multiforme.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Musculoskeletal and connective tissue disorders</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Pain in extremities (19%), arthralgia (12%), muscle spasms (12%).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>General disorders and administration site conditions</em></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp; Fatigue (30%), pyrexia (14%), chills (12%).</p><p>&nbsp;</p><p>&nbsp;</p><p>In the SAA study patient bone marrow aspirates were studied for cytogenetic abnormalities. New cytogenetic abnormalities were detected in 7 patients, including 5 patients with changes on chromosome 7.</p><p>&nbsp;</p><p>&nbsp;</p><p>Post-marketing experience</p><p><strong>&nbsp;</strong></p><p>The following adverse effects have been reported during post-approval use of Revolade. They comprise spontaneous case reports and serious adverse events from registries and post-marketing studies (including those in unapproved indications). A precise frequency cannot be given for these adverse effects.</p><p><em>Blood and lymphatic system disorders</em></p><p><em>&nbsp;</em></p><p>Progression to AML in patients with myelodysplastic syndrome.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Skin disorders</em></p><p>In patients taking eltrombopag doses above 100 mg/day reversible skin discolouration such as hyperpigmentation or skin yellowing were observed. These observations primarily relate to indications that require a high dosage of eltrombopag (such as SAA).</p><p>&nbsp;</p><p>--To reports any side effect(s):</p><p><strong><em>Saudi Arabia:</em></strong></p><p>Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>SFDA call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: <u>https://ade.sfda.gov.sa</u></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia: O Toll Free Number: 8001240078</p><p>O Phone: +966112658100</p><p>O Fax: +966112658107</p><p>O Email: adverse.events@novartis.com</p><p><strong><em>Other GCC States:</em></strong></p><p>-- Please contact the relevant competent authority.</p><p>&nbsp;</p><p>To report any complaint(s) : complaints.ksa@novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the clinical studies there was one report of overdose where the patient took 5000&nbsp;mg eltrombopag. Reported adverse events included mild skin rash, transient bradycardia, fatigue and elevated transaminases. Liver enzymes measured between day&nbsp;2 and day&nbsp;18 after ingestion peaked at 1.6‑fold the upper limit of normal for AST, 3.9‑fold ULN for ALT and 2.4‑fold ULN for total bilirubin. The maximum platelet count was 929,000/&micro;l. All adverse effects were completely reversible following discontinuation of eltrombopag.</p><p>&nbsp;</p><p>In the event of overdose the platelet count may increase excessively, which may result in thromboembolic complications. Therefore, if overdose occurs, oral administration of a metal cation-containing preparation, for example a calcium, aluminium or magnesium preparation, should be considered to chelate eltrombopag and thus reduce absorption. The platelet count should be closely monitored. Treatment with Revolade should then be reinitiated in accordance with dosage and administration recommendations (see &ldquo;Dosage/Administration&rdquo;).</p><p>&nbsp;</p><p>Since eltrombopag is not significantly renally excreted and is highly bound to plasma proteins, haemodialysis would not be expected to be an effective method to accelerate the elimination of eltrombopag.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code</p><p>B02BX05</p><p><strong>&nbsp;</strong></p><p>Pharmacodynamic properties</p><p><strong>&nbsp;</strong></p><p>Mechanism of action</p><p>&nbsp;</p><p>Eltrombopag olamine is an oral, small-molecule thrombopoietin receptor (TPO-R) agonist with a molecular weight of 564.65. Eltrombopag is practically insoluble in aqueous buffer solution across a pH range of 1 to 7.4 and is sparingly soluble in water.</p><p>Thrombopoietin (TPO) is the main cytokine involved in regulation of megakaryopoiesis and platelet production and is the endogenous ligand for the thrombopoietin receptor (TPO-R).</p><p>Eltrombopag interacts with the transmembrane domain of the human TPO-R and initiates signalling cascades similar, but not identical to, those initiated by endogenous thrombopoietin (TPO), inducing proliferation and differentiation of bone marrow progenitor cells.</p><p>&nbsp;</p><p>&nbsp;</p><p>Pharmacodynamics</p><p>&nbsp;</p><p>Eltrombopag differs from TPO with respect to its effects on platelet aggregation. Unlike TPO, eltrombopag does not lead to adenosine diphosphate (ADP)-induced aggregation in human platelets or induce P-selectin expression. Eltrombopag does not antagonise platelet aggregation induced by ADP or collagen.</p><p>&nbsp;</p><p>&nbsp;</p><p>Clinical efficacy</p><p>&nbsp;</p><p>Immune (idiopathic) thrombocytopenic purpura (ITP)</p><p><u>Adult patient population</u></p><p>The safety and efficacy of eltrombopag in adult patients previously treated for ITP were investigated in two randomised, double-blind, placebo-controlled studies (TRA102537 RAISE and TRA100773B) and two open-label studies (REPEAT TRA108057 and EXTEND TRA105325). The single-arm phase II study TAPER (CETB115J2411) evaluated the safety and efficacy of eltrombopag and its ability to induce a sustained response after treatment discontinuation in 105 adult ITP patients who relapsed or did not respond to first-line corticosteroid treatment.</p><p>&nbsp;</p><p><em>Double-blind, placebo-controlled studies</em></p><p>In TRA102537 (RAISE) 197 patients were randomised at a ratio of 2:1 to treatment with eltrombopag (n=135) or with placebo (n=62) and treated for up to 6 months.</p><p>With regard to the primary endpoint, &ldquo;achieving a platelet count between 50,000/&micro;l and 400,000/&micro;l&rdquo;, eltrombopag was significantly more effective than placebo (odds ratio [OR]: 8.2 [99% CI: 3.59, 18.73], p&lt;0.001). From day 15 a median platelet count above 50,000/&mu;l was maintained in the Revolade group at all visits during therapy; in contrast, the median platelet count in the placebo group</p><p>remained at &lt;30,000/&mu;l throughout the study.</p><p>At the start of the study clinically significant bleeding (WHO grades 2-4) was reported in 28% and 22% of patients in the placebo and eltrombopag groups, respectively. The proportion of patients with bleeding (grades 1-4) and clinically significant bleeding (grades 2-4) was reduced by approximately 50% in the eltrombopag group during the six-month treatment period.</p><p>Concomitant ITP therapies were able to be reduced or discontinued in 59% of patients receiving eltrombopag vs 32% of patients receiving placebo (p&lt;0.016).</p><p>Significantly fewer patients on eltrombopag required rescue treatment compared with those on placebo (19% vs 40%; p=0.001).</p><p>&nbsp;</p><p>In study TRA100773B 114 patients with previously treated ITP and a platelet count &lt;30,000/&micro;l were randomised at a ratio of 2:1; 76 patients received eltrombopag and 38 were given placebo. An increase in platelet count to 50,000/&mu;l on day 43 was rated as a response.</p><p>59% of patients on eltrombopag responded to the treatment compared with 16% of patients on placebo (OR: 9.6 [95% CI: 3.31, 27.86] p&lt;0.001). At the start of the study 61% of patients in the eltrombopag group and 66% of patients in the placebo group reported bleeding (grade 1-4). By day 43 39% of patients in the eltrombopag group had experienced bleeding compared with 60% in the placebo group (95% CI: 0.26, 0.83, p=0.021).</p><p>&nbsp;</p><p><em>Open-label, uncontrolled studies</em><em> </em></p><p>In study TRA108057 (REPEAT) 65 patients with ITP were treated intermittently with eltrombopag in cycles of up to 6 weeks interrupted by 4week off-therapy periods.</p><p>The primary endpoint of the study was the proportion of patients who achieved a platelet count of</p><p>50,000/&mu;l and at least 2x baseline in cycle 2 or 3, provided there had been a response in cycle 1.</p><p>Of the 65 patients in total, 52 responded to eltrombopag in cycle 1 and 45 of these also responded in the second or third treatment cycle.</p><p>Both overall bleeding (WHO grades 1-4) and clinically significant bleeding (WHO grades 2-4) decreased during the treatment phases in each cycle.</p><p>&nbsp;</p><p>In study TRA105325 (EXTEND) eltrombopag was administered to 302 patients who had previously taken part in an eltrombopag study. The duration of treatment ranged from 2 days to 8.76 years (median: 2.37 years). The mean daily dose was 50.2 mg (SD 21.56). The median baseline platelet count prior to eltrombopag administration was 19,000/ml. The eltrombopag dose was able to be adjusted individually.</p><p>The median platelet counts after 1, 2, 3, 4, 5, 6 and 7 years of the study were 85,000//l, 85,000/l, 105,000/ml, 64,000/ml, 75,000/l, 119,000/l and 76,000/ml.</p><p>&nbsp;</p><p>&nbsp;</p><p>Study CETB115J2411 (TAPER) was a single-arm phase II study in ITP patients treated with eltrombopag after failure of first-line corticosteroid treatment irrespective of time since diagnosis. A total of 105 patients were enrolled in the study and started treatment with 50 mg eltrombopag once daily (25 mg once daily for patients of East-/Southeast Asian ancestry except for Japanese patients in Japan, who received 12.5 mg once daily). The dose of eltrombopag was adjusted during the treatment period based on individual platelet counts with the goal to achieve a platelet count &ge;100,000/&micro;l.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Results of primary analysis of sustained response to treatment</em></p><p>In patients who reached a platelet count of &ge;100,000/&mu;l and maintained a platelet count of &ge;70,000/&mu;l for 2 months eltrombopag was able to be discontinued and treatment ended. To be considered as having achieved a sustained response to treatment, a patient had to maintain a platelet count of &ge;30,000/&mu;l, without bleeding adverse events occurring or rescue therapy being required, both during treatment tapering and following discontinuation of treatment until month 12.</p><p>In terms of tapering, the dose was reduced by 25 mg every 2 weeks if platelet counts were stable, followed by a dose of 25 mg on alternate days for 2 weeks until treatment discontinuation.</p><p>The duration of tapering was individualised depending on the starting dose and patient response. The dose was reduced in smaller decrements of 12.5 mg every second week for patients of East-/Southeast Asian ancestry. If a relapse (defined as platelet count of &lt;30,000/&mu;l) occurred during the 12 month treatment period, patients were offered a new course of Revolade/Promacta at the appropriate starting dose.</p><p>The study met the primary endpoint by demonstrating that eltrombopag was able to induce a sustained response to treatment, without bleeding events occurring or rescue therapy being required, by month 12 in 32 of the 105 enrolled patients (30.5%; p&lt;0.0001; 95% CI: 21.9, 40.2).</p><p>89 patients (84.8%) achieved a complete response (platelet count &ge;100,000/&mu;l) and 65 patients (61.9%) maintained the complete response for at least 2 months with no platelet counts decreasing to &lt;70,000/&mu;l. 44 patients (41.9%) were able to be tapered off eltrombopag through treatment discontinuation while maintaining a platelet count of &ge;30,000/&mu;l without bleeding adverse events occurring or rescue therapy being required (Table 8).</p><p>The median duration of sustained response after treatment discontinuation to month 12 was 33.3 weeks (range: 4 51).</p><p>The overall safety analysis is consistent with previously reported data and the benefit-risk assessment remained unchanged for the use of eltrombopag in patients with ITP.</p><p>&nbsp;</p><p><strong>Table&nbsp;8&nbsp; Proportion of patients with sustained response to treatment at month&nbsp;12 (full analysis set) during taper</strong></p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td><p><strong>&nbsp;</strong></p></td><td colspan="2"><p><strong>Overall patient population<br />N=105</strong></p></td><td colspan="2"><p><br /><strong>Hypothesis testing</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>n (%)</strong></p></td><td><p><strong>95%&nbsp;CI</strong></p></td><td><p><strong>p‑value</strong></p></td><td><p><strong>Rejection of null hypothesis</strong></p></td></tr></thead><tbody><tr><td><p>Step&nbsp;1:&nbsp;&nbsp; Patients who reached platelet count of &ge;100,000/&mu;l at least once</p></td><td><p>89 (84.8)</p></td><td><p>(76.4, 91.0)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Step&nbsp;2:&nbsp;&nbsp; Patients who maintained a stable platelet count for 2&nbsp;months after reaching 100,000/&mu;l (no counts below 70,000/&mu;l)</p></td><td><p>65 (61.9)</p></td><td><p>(51.9, 71.2)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Step&nbsp;3:&nbsp;&nbsp; Patients who were able to discontinue the medicinal product by tapering off, maintaining a platelet count of &ge;30,000/&mu;l without bleeding adverse events occurring or rescue therapy being required</p></td><td><p>44 (41.9)</p></td><td><p>(32.3, 51.9)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Step&nbsp;4:&nbsp;&nbsp; Patients with sustained response after treatment until month&nbsp;12, maintaining a platelet count of &ge;30,000/&mu;l without bleeding adverse events occurring or rescue therapy being required</p></td><td><p>32 (30.5)</p></td><td><p>(21.9, 40.2)</p></td><td><p>&lt;0.0001*</p></td><td><p>Yes</p></td></tr><tr><td colspan="5"><p>N: The total number of patients in the treatment group. It is the denominator for percentage (%) calculation.</p><p>n: Number of patients who are in the corresponding category.</p><p>The 95%&nbsp;CI for the frequency distribution was computed using the Clopper‑Pearson exact method.</p><p>The Clopper‑Pearson method is used to test whether the proportion of responders is greater than 15%.</p><p>CI and p‑values are reported.</p><p>*Indicates statistical significance (one-sided) at the 0.05&nbsp;level.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Results of an analysis of early response to treatment by time since ITP diagnosis</em></p><p>An ad-hoc analysis was conducted on the n=105 patients by time since ITP diagnosis to assess the early response to eltrombopag treatment across four different ITP duration categories (newly diagnosed ITP &lt;3 months, persistent ITP 3 to &lt;6 months, persistent ITP 6 to &le;12 months and chronic ITP &gt;12 months).</p><p>49% of patients (n=51) had an ITP duration of &lt;3 months, 20% (n=21) of 3 to &lt;6 months, 17% (n=18) of 6 to &le;12 months and 14% (n=15) of &gt;12 months.</p><p>Until the cut-off date (22 October 2021) patients were treated with eltrombopag for a median (25th to 75th percentile) duration of 6.2 months (2.3 to 12.0). The median (25th to 75th percentile) platelet count at baseline was 16,000/&mu;l (7,800 to 28,000/&mu;l).</p><p>A platelet count response, defined as a platelet count of &ge;50,000/&mu;l at least once by week 9 without rescue therapy, was achieved in 84% (95% CI: 71%, 93%) of newly diagnosed patients (ITP duration &lt;3 months), 91% (95% CI: 70%, 99%) and 94% (95% CI: 73%, 100%) of persistent ITP patients (i.e. with ITP diagnosis 3 to &lt;6 months and 6 to &le;12 months, respectively) and in 87% (95% CI: 60%, 98%) of chronic ITP patients.</p><p>The proportion of patients with a complete response, defined as a platelet count of &ge;100,000/&mu;l at least once by week 9 without rescue therapy, was 75% (95% CI: 60%, 86%) in newly diagnosed patients (ITP duration &lt;3 months), 76% (95% CI: 53%, 92%) and 72% (95% CI: 47%, 90%) in persistent ITP patients (ITP duration 3 to &lt;6 months and 6 to &le;12 months, respectively) and 87% (95% CI: 60%, 98%) in chronic ITP patients.</p><p>The proportion of patients with a durable response, defined as a platelet count of &ge;50,000/&mu;l for at least 6 out of 8 consecutive assessments without rescue therapy during the first 6 months on study, was 71% (95% CI: 56%, 83%) in newly diagnosed ITP patients, 81% (95% CI: 58%, 95%) and 72% (95% CI: 47%, 90%) in persistent ITP patients (ITP duration 3 to &lt;6 months and 6 to &le;12 months, respectively) and 80% (95% CI: 52%, 96%) in chronic ITP patients.</p><p>&nbsp;When assessed with the WHO Bleeding Scale, the proportion of newly diagnosed and persistent ITP patients without bleeding at week 4 ranged from 88% to 95%, compared to 37% to 57% at baseline. For chronic ITP patients it was 93%, compared to 73% at baseline.</p><p>&nbsp;</p><p>The safety of eltrombopag was consistent across all ITP categories and in line with its known safety profile.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric ITP patient population</u></p><p>The safety and efficacy of eltrombopag in paediatric patients aged from 1 year with previously treated ITP were investigated in two double-blind studies.</p><p>TRA115450 (PETIT2): The study comprised a 13-week double-blind, placebo-controlled phase (part 1) followed by a 24-week open-label phase (part 2). The patients had been refractory to two or three previous ITP therapies (IVIG, corticosteroids, anti-D immunoglobulin, rituximab) or had subsequently suffered a relapse or could not continue other ITP treatments for medical reasons and had a platelet count of &lt;30,000/&micro;l. 92 patients were randomised (2:1) to eltrombopag (n = 63) or placebo (n = 29) in three age cohorts. The eltrombopag dose was adjusted and titrated based on individual platelet counts, age, body weight and ethnicity (non-Asian vs Asian descent). The primary endpoint was a sustained response, defined as the proportion of patients on eltrombopag that achieved platelet counts of</p><p>&ge;50&lsquo;000/&micro;l between week 5 and week 12 of the double-blind, randomised phase for at least 6 of the 8 weeks (without use of rescue medication).</p><p>Overall, a significantly greater proportion of eltrombopag patients (39.7%) achieved the primary endpoint compared with placebo patients (3.4%) (OR: 18.0 [95% CI: 2.3, 140.9] p &lt; 0.001). The result was similar across all three age cohorts (Table 9).</p><p>Table 9: PETIT2: Sustained platelet count response rates in paediatric patients with ITP lasting at least 12 months by age cohort</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Eltrombopag</p><p><strong>&nbsp;</strong></p><p>n/N (%) [95% CI]</p></td><td><p>Placebo</p><p><strong>&nbsp;</strong></p><p>n/N (%) [95% CI]</p></td></tr><tr><td><p>Cohort 1 (12 to 17 years of age)</p></td><td><p>9/23 (39.1%)</p></td><td><p>1/10 (10.0%)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>[20%, 61%]</p></td><td><p>[0%, 45%]</p></td></tr><tr><td><p>Cohort 2 (6 to 11 years of age)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>11/26 (42.3%)</p></td><td><p>0/13 (0%)</p></td></tr><tr><td><p>Cohort 3 (1 to 5 years of age)</p></td><td><p>[23%, 63%]</p></td><td><p>[n/a]</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>5/14 (35.7%)</p></td><td><p>0/6 (0%)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>[13%, 65%]</p></td><td><p>[n/a]</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Significantly fewer eltrombopag patients required rescue treatment during the randomised phase compared to placebo patients (12/63 vs 7/29, p = 0.032).</p><p>After 12 weeks eltrombopag had no significant effect on WHO grade 2-4 bleeding (4.8% for eltrombopag vs 6.9%), but did reduce WHO grade 1-4 bleeding to 36.5% versus 55.2% on placebo. WHO grade 4 bleeding did not occur in PETIT2.</p><p><em>TRA108062 (PETIT)</em>: 67 paediatric patients who had had ITP for 6 months were included. This criterion does not correspond to chronic ITP lasting for at least 12 months. PETIT was planned as a phase II dose-finding study. The primary endpoint was the proportion of patients who achieved platelet counts of &ge;50&lsquo;000/&micro;l between week 1 and week 6 of the randomised phase at least once.</p><p>&nbsp;</p><p>Patients had been refractory to at least one prior ITP therapy or had subsequently suffered a relapse and had a platelet count of &lt;30,000/&micro;l. Approximately 85% of the patients had had at least 2 previous treatments (IVIG, corticosteroids, etc.). During the randomised study phase patients were randomised (2:1) to eltrombopag (n = 45) or placebo (n = 22) in three age cohorts. The eltrombopag dose could be adjusted based on individual platelet counts.</p><p>&nbsp;</p><p>Overall, a significantly greater proportion of eltrombopag patients (62.2%) achieved the primary endpoint compared with placebo patients (31.8%) (OR: 4.3 [95% CI: 1.4, 13.3] p &lt; 0.011). The results are summarised for all three age cohorts in Table 10. In the 1-5 years age group no effective dose could be determined as the spontaneous remission rate in the placebo group was very high due to the 6-month inclusion criterion.</p><p>Table 10: PETIT: Platelet count response rates in paediatric patients with ITP lasting at least 12 months</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Eltrombopag</p><p><strong>&nbsp;</strong></p><p>n/N (%) [95% CI]</p></td><td><p>Placebo</p><p><strong>&nbsp;</strong></p><p>n/N (%) [95% CI]</p></td></tr><tr><td><p>Cohort 1 (12 to 17 years of age)</p></td><td><p>10/16 (62.5%)</p></td><td><p>0/8 (0%)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>[35%, 85%]</p></td><td><p>[n/a]</p></td></tr><tr><td><p>Cohort 2 (6 to 11 years of age)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>12/19 (63.2%)</p></td><td><p>3/9 (33.3%)</p></td></tr><tr><td><p>Cohort 3 (1 to 5 years of age)</p></td><td><p>[44%, 90%]</p></td><td><p>[7%, 70%]</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>6/10 (60.0%)</p></td><td><p>4/5 (80.0%)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>[26%, 88%]</p></td><td><p>[28%, 99%]</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Significantly fewer eltrombopag patients required rescue medication during the randomised phase compared to placebo patients (6/45 vs 11/22, p = 0.002).</p><p>During PETIT&rsquo;s double-blind phase 73.3% of patients on eltrombopag experienced WHO grade 1-4 bleeding and 26.7% experienced grade 2-4 bleeding. On placebo the corresponding incidences were 90.9% and 59.1%, respectively.</p><p>&nbsp;</p><p>In the global health score questionnaire eltrombopag did not demonstrate any significant benefit or positive trend compared to placebo over a total of 6 weeks during PETIT.</p><p>&nbsp;</p><p>Chronic hepatitis C-associated thrombocytopenia</p><p>The efficacy and safety of eltrombopag for the treatment of thrombocytopenia in patients with HCV infection were evaluated in two randomised, double-blind, placebo-controlled studies. ENABLE 1 utilised peginterferon alfa-2a plus ribavirin for antiviral treatment and ENABLE 2 utilised peginterferon alfa-2b plus ribavirin. In both studies patients with a platelet count of &lt;75,000/&mu;l were enrolled. The patients were stratified by platelet count (&lt;50,000/&micro;l vs &ge;50,000/&micro;l to &lt;75,000/&micro;l), screening HCV RNA (&lt;800,000 IU/ml vs &ge;800,000 IU/ml) and HCV genotype (genotype 2/3 vs genotype 1/4/6).</p><p>&nbsp;</p><p>During the induction phase (prior to antiviral treatment) patients received open-label eltrombopag to increase the platelet count to &ge;90,000/&micro;l (ENABLE 1) and &ge;100,000/&micro;l (ENABLE 2). Eltrombopag was administered at a starting dose of 25 mg once daily for two weeks, then increased in 25 mg increments at two to three week intervals to achieve the required platelet count for phase 2 of the study. The maximum induction phase duration allowed was 9 weeks. Once the desired platelet count was achieved, the patients were transferred to the controlled antiviral therapy phase and randomised to eltrombopag or placebo at a ratio of 2:1. Eltrombopag was administered in combination with antiviral treatment for up to 48 weeks.</p><p>&nbsp;</p><p>The primary efficacy endpoint for both studies was sustained virological response (SVR = HCV RNA not detectable after 24 weeks of antiviral therapy). Approximately 70% of patients were genotype 1/4/6 and 30% were genotype 2/3. Approximately 30% of patients had been treated with prior HCV therapies, primarily pegylated interferon plus ribavirin. The median platelet count at the start of the study (approximately 60,000/&micro;l) was similar in all treatment groups. The median time to achieve the target platelet count of &ge;90,000/&micro;l (ENABLE 1) or &ge;100,000/&micro;l (ENABLE 2) was two weeks.</p><p>&nbsp;</p><p>In both HCV studies a significantly greater proportion of patients treated with eltrombopag achieved SVR compared to those treated with placebo (see Table 11). In patients with prior interferon treatment 12% of patients on eltrombopag demonstrated SVR compared to 5% in on placebo. No advantage of eltrombopag over placebo was discernible in the subgroup of patients &ge;65 years of age.</p><p>&nbsp;</p><p>Table 11: ENABLE 1 and ENABLE 2 virological response</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>ENABLE 1<sup>a</sup></strong></p></td><td colspan="2"><p><strong>ENABLE 2<sup>b</sup></strong></p></td></tr><tr><td><p><strong>Pre-antiviral treatment</strong></p><p><strong>phase</strong></p></td><td colspan="2"><p>N = 715</p></td><td colspan="2"><p>N = 805</p></td></tr><tr><td><p>Percentage of patients who achieved target platelet counts and in whom antiviral</p><p>therapy was initiated<strong><sup>c</sup></strong></p></td><td colspan="2"><p>95%</p></td><td colspan="2"><p>94%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Eltrombopag</strong></p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>Eltrombopag</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Antiviral treatment phase</strong></p></td><td><p><strong>n=450</strong></p><p><strong>%</strong></p></td><td><p><strong>n=232</strong></p><p><strong>%</strong></p></td><td><p><strong>n=506</strong></p><p><strong>%</strong></p></td><td><p><strong>n=253</strong></p><p><strong>%</strong></p></td></tr><tr><td><p><strong>Overall SVR</strong></p></td><td><p>23</p></td><td><p>14</p></td><td><p>19</p></td><td><p>13</p></td></tr><tr><td><p>HCV genotype 2, 3</p></td><td><p>35</p></td><td><p>24</p></td><td><p>34</p></td><td><p>25</p></td></tr><tr><td><p>HCV genotype 1, 4, 6</p></td><td><p>18</p></td><td><p>10</p></td><td><p>13</p></td><td><p>7</p></td></tr></tbody></table><p>&nbsp;</p><p>a Eltrombopag in combination with peginterferon alfa-2a (180 &micro;g once weekly for 48 weeks for genotypes 1 or 4; 24 weeks for genotypes 2 or 3) plus ribavirin (800-1200 mg/day in 2 divided oral doses)</p><p>b Eltrombopag in combination with peginterferon alfa-2b (1.5&micro;g/kg once weekly for 48 weeks for genotype 1 or 4; 24 weeks for genotype 2 or 3) plus ribavirin (800-1400 mg orally)</p><p>c Target was a platelet count &ge;90,000/&micro;l (ENABLE 1) or &ge;100,000/&micro;l (ENABLE 2).</p><p>&nbsp;</p><p>&nbsp;</p><p>Significantly fewer patients on eltrombopag required an antiviral dose reduction compared with those on placebo (55% vs 73%). The incidence of premature withdrawal from antiviral therapy was significantly lower in patients on eltrombopag than in those on placebo (45% vs 60%, p&le;0.0001). 76% of patients on eltrombopag had minimum platelet counts of &ge;50,000/&micro;l compared to 19% on placebo. The proportion of patients who had minimum platelet counts fall to &lt;25,000/&micro;l during treatment was 3% on eltrombopag compared 20% on placebo. In the eltrombopag group the SVR rate in patients with high viral loads (&gt;800,000) was 18% compared to 8% in the placebo group.</p><p>&nbsp;</p><p>Revolade has not been tested in combination with HCV protease inhibitors (e.g. boceprevir, telaprevir).</p><p>&nbsp;</p><p>&nbsp;</p><p>Definitive immunosuppressive therapy-naive severe aplastic anaemia study</p><p><strong>&nbsp;</strong></p><p>Eltrombopag in combination with horse antithymocyte globulin (h-ATG) and ciclosporin was investigated in a single-arm, single-centre, open-label, sequential-cohort study in patients with severe aplastic anaemia who had not received prior definitive immunosuppressive therapy (i.e. ATG therapy, alemtuzumab or high-dose cyclophosphamide). The various cohorts differed in the start day and duration of eltrombopag treatment and the initiation of low-dose ciclosporin (maintenance dose) in patients who achieved a haematologic response at 6 months. A total of 153 patients received eltrombopag in sequential cohorts:</p><p>Eltrombopag on day 14 to month 6 (D14-M6) plus h-ATG and ciclosporin (the study&rsquo;s cohort 1 regimen, n=30).</p><p>Eltrombopag on day 14 to month 3 (D14-M3) plus h-ATG and ciclosporin (the study&rsquo;s cohort 2 regimen, n=31), with half of the patients eligible to receive low-dose ciclosporin (maintenance dose) if they had achieved a haematologic response at 6 months.</p><p>Eltrombopag on day 1 to month 6 (D1-M6) plus h-ATG and ciclosporin (the study&rsquo;s cohort 3 regimen, n=92), with all patients eligible to receive low-dose ciclosporin (maintenance dose) if they had achieved a haematologic response at 6 months.</p><p>&nbsp;</p><p>The starting dose of eltrombopag for adults and paediatric patients aged 12 to 17 years was 150 mg once daily (a reduced dose of 75 mg was administered to East and Southeast Asians), 75 mg once daily for patients aged 6 to 11 years (a reduced dose of 37.5 mg was administered to East and Southeast Asians) and 2.5 mg/kg once daily for patients aged 2 to 5 years (a reduced dose of 1.25 mg/kg was administered to East and Southeast Asians). The dose of eltrombopag was reduced if the platelet count exceeded 200,000/&mu;l and interrupted and reduced if it exceeded 400,000/&mu;l.</p><p>All patients received 40 mg/kg/day h-ATG on days 1 to 4 of the six-month treatment period and a total daily dose of 6 mg/kg/day ciclosporin for 6 months in patients aged 12 years and over or a total daily dose of 12 mg/kg/day for 6 months in patients aged 2 to 11 years. A maintenance dose of 2 mg/kg/day ciclosporin was administered for an additional 18 months to 15 patients who achieved a haematologic response at 6 months in the eltrombopag D14-M3 cohort and all patients who achieved a haematologic response at 6 months in the eltrombopag D1-M6 cohort.</p><p>Data from the recommended schedule of eltrombopag on day 1 to month 6 in combination with h-ATG and ciclosporin (the study&rsquo;s cohort 3 regimen) are presented below. This cohort had the highest complete response rates.</p><p>In the eltrombopag D1-M6 cohort the median age was 28.0 years (range 5 to 82 years), with 16.3% and 28.3% of patients &ge;65 years of age and &lt;18 years of age, respectively. 45.7% of patients were male and the majority of patients were Caucasian (62.0%).</p><p>The efficacy of eltrombopag in combination with h-ATG and ciclosporin was established on the basis of complete haematological response at 6 months. A complete response was defined as haematological parameters meeting all three of the following values on two consecutive serial blood count measurements at least one week apart: absolute neutrophil count (ANC) &gt;1,000/&mu;l, platelet count</p><p>&gt;100,000/&mu;l and haemoglobin &gt;10 g/dl. A partial response was defined as blood counts no longer meeting the standard criteria for severe pancytopenia in severe aplastic anaemia equivalent to two of the following values on two consecutive serial blood count measurements at least one week apart: ANC &gt;500/&mu;l, platelet count &gt;20,000/&mu;l or reticulocyte count &gt;60,000/&mu;l.</p><p>&nbsp;</p><p>Table 12&nbsp;&nbsp; Efficacy results in definitive immunosuppressive therapy-naive SAA patients</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Elt D1-M6 + h-ATG + ciclosporin</strong></p><p><strong>N=92</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Month 3, n<sup>a</sup></strong></p></td><td colspan="2"><p><strong>88</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Overall response, n (%)</p><p>[95% CI]</p></td><td colspan="2"><p>66 (75.0)</p><p>[64.6, 83.6]</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Complete response, n (%)</p><p>[95% CI]</p></td><td colspan="2"><p>24 (27.3)</p><p>[18.3, 37.8]</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Month 6, n<sup>a</sup></strong></p></td><td colspan="2"><p><strong>87</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Overall response, n (%)</p><p>[95% CI]</p></td><td colspan="2"><p>69 (79.3)</p><p>[69.3, 87.3]</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Complete response, n (%)</p><p>[95% CI]</p></td><td colspan="2"><p>38 (43.7)</p><p>[33.1, 54.7]</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Median duration of overall response, n<sup>b</sup></p></td><td colspan="2"><p>70</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Months (95% CI)</p></td><td colspan="2"><p>24.3 (21.4, NE)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p>&nbsp;</p></td><td colspan="2"><p><strong>Elt D1-M6 + h-ATG + ciclosporin</strong></p><p><strong>N=92</strong></p></td></tr><tr><td colspan="3"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="3"><p>Median duration of complete response, n<sup>b</sup></p><p>Months (95% CI)</p></td><td colspan="2"><p>46</p><p>24.3 (23.0, NE)</p></td></tr><tr><td colspan="5"><p><em><sup>n</sup></em><em> </em><em>The number of patients who reached the 3- or 6-month assessment or withdrew earlier is the denominator for percentage calculation.</em></p><p><em><sup>b</sup></em><em> </em><em>The number of patients who responded at any time. NE = not estimable</em></p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>The overall and complete haematologic response rates were 56.4% and 38.5%, respectively, in year 1 (n=78) and 38.7% and 30.6%, respectively, in year 2 (n=62).</p><p>&nbsp;</p><p><u>Paediatric patients</u></p><p>37 patients aged 2 to 17 years were enrolled in the single-arm, sequential-cohort study. Of the</p><p>36 patients who reached the 6-month assessment point or withdrew earlier, the complete response rate at 6 months was 30.6% (0/2 in patients aged 2 to 5 years, 1/12 in patients aged 6 to 11 years and 10/22 in patients aged 12 to 17 years) and the overall response rate at 6 months was 72.2% (2/2 in patients aged 2 to 5 years, 7/12 in patients aged 6 to 11 years and 17/22 in patients aged 12 to 17 years). Of 25 evaluable patients in the eltrombopag D1-M6 cohort the complete response rate at 6 months was 28% and the overall response rate at 6 months was 68.0%.</p><p>&nbsp;</p><p>Refractory severe aplastic anaemia</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Eltrombopag was studied in a single-arm, single-centre, open-label study in 43 patients with severe aplastic anaemia who had an insufficient response to at least one prior immunosuppressive therapy and who had a platelet count &le;30,000/&micro;l.</p><p>&nbsp;</p><p>Eltrombopag was administered at a starting dose of 50 mg once daily for two weeks and then increased at weekly intervals in 25 mg increments up to a maximum dose of 150 mg once daily.</p><p>&nbsp;</p><p>The primary endpoint was haematological response assessed after 12 weeks of treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p>Haematological response was defined as meeting one or more of the following criteria: 1) platelet count increase to 20,000/&mu;l above baseline or stable platelet counts with transfusion independence for a minimum of 8 weeks; 2) haemoglobin concentration increase by &gt;1.5 g/dl or a reduction of RBC transfusions by &ge;4 units for 8 consecutive weeks; 3) absolute neutrophil count (ANC) increase of 100% or an ANC increase &gt;0.5 x 10<sup>9</sup>/l.</p><p>&nbsp;</p><p>The treated population had a median age of 45 years (age range 17 to 77 years) and 56% of patients were male. At the start of the study the median platelet count was 20,000/&mu;l, haemoglobin concentration was 8.4 g/dl and ANC was 0.58 x 10<sup>9</sup>/l. 68% of patients were RBC transfusion- dependent and 91% were platelet transfusion-dependent.</p><p>&nbsp;</p><p>The majority of patients (84%) had received at least 2 prior immunosuppressive therapies. Three patients had cytogenetic abnormalities at the start of the study.</p><p>Eltrombopag treatment was discontinued after 16 weeks if no haematological response or transfusion independence was observed. Patients who responded to treatment continued therapy in an extension phase of the study.</p><p>After 12-16 weeks the haematological response rate was 40% (95% CI: 25, 56).</p><p>During the extension phase bi- or trilineage blood cell responses were observed in 9/17 patients in total: in 4/17 patients after 12-16 weeks, in 1 further patient after 6 months and in two further patients after 9 and 12 months, respectively.</p><p>&nbsp;</p><p>The longest platelet transfusion-free interval in responders ranged from 8 to 1,096 days with a median of approximately 200 days. The longest RBC transfusion-free period in responders ranged from 15 to 1,082 days with a median of approximately 208 days.</p><p>&nbsp;</p><p>4 patients who tapered off treatment with eltrombopag following a trilineage response maintained a response for a median follow-up period of 8 months (7.2, 10.6 months).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacokinetics</u></p><p>&nbsp;</p><p>Absorption</p><p>&nbsp;</p><p>The peak concentration of eltrombopag is achieved 2 to 6 hours after oral administration. The absolute bioavailability of eltrombopag in humans has not been established.</p><p><em>Food effect</em></p><p>Administration of a single 50 mg eltrombopag dose as a film-coated tablet with a standard breakfast (high calorie and high fat) that also included dairy products reduced plasma eltrombopag AUC0-inf by 59% and Cmax by 65%.</p><p>Upon administration of a single dose of 25 mg eltrombopag powder for oral suspension with a calcium-rich meal with a moderate fat and calorie content eltrombopag plasma AUC(0-inf) decreased by 75% (90% CI: 71%, 88%) and Cmax by 79% (90% CI: 76%, 82%). Upon administration of a single dose of 25 mg eltrombopag powder for oral suspension 2 hours before a calcium-rich meal the effect was weaker, with eltrombopag plasma AUC(0-inf) decreasing by 20% (90% CI: 9%, 29%) and Cmax by 14% (90% CI: 2%, 25%).</p><p>&nbsp;</p><p>Food low in calcium (&lt;50 mg calcium) such as fruit, lean ham, beef, unfortified fruit juice, soya milk and cereals (no added calcium, magnesium or iron) had no significant effect on eltrombopag exposure, regardless of calorie and fat content.</p><p>&nbsp;</p><p>&nbsp;</p><p>Distribution</p><p>&nbsp;</p><p>Eltrombopag is &gt;99.9% bound to human plasma proteins.</p><p>&nbsp;</p><p>&nbsp;</p><p>Metabolism</p><p>&nbsp;</p><p>Eltrombopag is primarily metabolised by cleavage, oxidation and conjugation with glucuronic acid (UGT1A1 and UGT1A3), glutathione or cysteine. In a human radiolabel study eltrombopag accounted for approximately 64% of plasma radiocarbon AUC(0-inf). Minor metabolites, each accounting for</p><p>&lt;10% of plasma radioactivity and arising from glucuronidation and oxidation, were also detected. Around 20% of the dose was metabolised by oxidation. <em>In vitro </em>studies identified CYP1A2 and CYP2C8 as the isoenzymes responsible for oxidative metabolism.</p><p>&nbsp;</p><p>&nbsp;</p><p>Elimination</p><p>&nbsp;</p><p>Eltrombopag is extensively metabolised. 59% of eltrombopag is excreted via the faeces (with 20% of the dose as unchanged eltrombopag). 31% of the dose is found in the urine as metabolites. The unchanged parent compound is not detectable in the urine.</p><p>The plasma elimination half-life of eltrombopag is 21-32 hours.</p><p>&nbsp;</p><p>&nbsp;</p><p>Pharmacokinetics in special populations</p><p>&nbsp;</p><p><em>Gender:</em></p><p>Based on two population pharmacokinetic analyses of eltrombopag in ITP and HCV patients plasma AUC(0-) was approx. 24-41% higher in female than in male patients.</p><p>&nbsp;</p><p><em>Ethnicity:</em></p><p>Based on two population pharmacokinetic analyses of eltrombopag in ITP and HCV patients those of Asian descent (i.e. Japanese, Chinese, Taiwanese and Korean patients) had approximately 50-55% higher plasma AUC0-&infin; than non-Asian patients of mainly Caucasian descent.</p><p>&nbsp;</p><p><em>Paediatric ITP population</em></p><p>The pharmacokinetics of eltrombopag dosed once daily were evaluated in two studies (TRA108062/PETIT and TRA115450/PETIT-2) in 168 paediatric ITP patients aged 1-17 years. Apparent eltrombopag plasma clearance following oral administration (CL/F) increased with increasing body weight. The influence of ethnicity and gender on estimated eltrombopag plasma CL/F was consistent in paediatric and adult patients. Paediatric ITP patients of Asian descent exhibited approximately 43% higher eltrombopag plasma AUC(0-) than patients of non-Asian descent. Female paediatric ITP patients exhibited approximately 25% higher eltrombopag plasma AUC(0-) than male patients.</p><p>The estimated pharmacokinetic parameters of eltrombopag in paediatric ITP patients are presented in Table 13.</p><p>Table 13: Mean (95% CI) steady-state plasma eltrombopag pharmacokinetic parameters (50 mg once daily) in paediatric ITP patients</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Age</strong></p></td><td><p><strong>C</strong><strong>max</strong></p><p><strong>(&micro;g/ml)</strong></p></td><td><p><strong>AUC</strong><strong>(0-)</strong></p><p><strong>(&micro;g.hr/ml)</strong></p></td></tr><tr><td><p>Adults (n = 108)<sup>a</sup></p></td><td><p>7.03</p><p>(6.44, 7.68)</p></td><td><p>101</p><p>(91.4, 113)</p></td></tr><tr><td><p>12 to 17 years (n = 62)<sup>b</sup></p></td><td><p>6.80</p><p>(6.17, 7.50)</p></td><td><p>103</p><p>(91.1, 116)</p></td></tr><tr><td><p>6 to 11 years (n = 68)<sup>b</sup></p></td><td><p>10.3</p><p>(9.42, 11.2)</p></td><td><p>153</p><p>(137, 170)</p></td></tr><tr><td><p>1 to 5 years (n = 38)<sup>b</sup></p></td><td><p>11.6</p><p>(10.4, 12.9)</p></td><td><p>162</p><p>(139, 187)</p></td></tr></tbody></table><p>aData from adult patients with ITP from studies TRA100773A, TRA100773B and TRA108109.</p><p><sup>b</sup>Data in the paediatric population presented as the geometric mean (95% CI). AUC(0-) and Cmax are based on population pharmacokinetic post hoc estimates.</p><p>&nbsp;</p><p>The median daily doses administered in the paediatric studies in the individual age groups were as follows:</p><p>1 to 5 years (n = 40): 37.0 mg (range 8.8 mg-68.0 mg)</p><p>6 to 11 years (n = 70): 57.6 mg (range 4.7 mg-68.0 mg)</p><p>12 to 17 years (n = 61): 64.0 mg (range 18.6 mg-74.41 mg)</p><p>&nbsp;</p><p>&nbsp;</p><p>Approximately 50% of patients aged 6-17 years in the TRA115450/PETIT2 study had their dose increased to the maximum dose of 75 mg.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>Age-specific differences in the pharmacokinetics of eltrombopag were evaluated using a population pharmacokinetic analysis of data from 28 healthy subjects and 635 patients with HCV aged 19 to 74 years. Based on model estimates elderly patients (&gt;60 years) had an approx. 36% higher plasma AUC(0-inf) than younger patients (see &ldquo;Dosage/Administration&rdquo;).</p><p>&nbsp;</p><p><em>Renal impairment:</em></p><p>Eltrombopag is not excreted via the kidneys. In cases of severe renal impairment the AUC(0-inf) is reduced by 60%. This may be a consequence of dysproteinaemia.</p><p>&nbsp;</p><p><em>Hepatic impairment:</em></p><p>The administration of a single 50 mg dose resulted in an increase in eltrombopag AUC(0-inf) of 41% in subjects with mild hepatic impairment, 93% in subjects with moderate hepatic impairment and 80% in subjects with severe hepatic impairment compared with healthy subjects.</p><p>&nbsp;</p><p>The influence of hepatic impairment on the pharmacokinetics of eltrombopag following repeat administration was evaluated using a population pharmacokinetic analysis in 28 healthy adults and 714 patients with hepatic impairment (673 patients with HCV and 41 patients with chronic liver disease of other aetiology). Of the 714 patients 642 had mild hepatic impairment, 67 had moderate hepatic impairment and 2 had severe hepatic impairment. Compared to healthy subjects patients with mild hepatic impairment (Child-Pugh score 5 and 6) and patients with moderate hepatic impairment (Child-Pugh score 7-9) had approximately 111% (95% CI: 45% to 283%) and 183% (95% CI: 90% to 450%) higher AUC(0-&tau;), respectively. In patients with hepatic impairment the exposure in HCV patients was more markedly elevated (see &ldquo;Dosage/Administration&rdquo; and &ldquo;Warnings/precautions&rdquo;).</p><p>&nbsp;</p><p><em>SAA patients</em></p><p>Pharmacokinetic data for SAA patients are limited to preliminary results in 23 SAA patients (including 3 adolescents). The dose-normalised exposure (AUC(0-&tau;), Cmax) in these patients was 2 to 3 times higher than the exposure observed in healthy subjects or ITP patients and corresponded approximately to that in HCV patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Safety pharmacology and repeated-dose toxicity</em></p><p><em>&nbsp;</em></p><p>Treatment-related, dose-dependent and time-dependent cataracts were detected in rodents. These occurred in mice after 6 weeks and in rats after 28 weeks of administering doses equivalent to 3 times the systemic exposure (AUC) in adult HCV patients (100 mg/day) and &ge;6 times the systemic exposure (AUC) in adult ITP patients (75 mg/day). Longer treatment durations (13 weeks and 39 weeks, respectively) resulted in even smaller safety margins for ITP and HCV patients.</p><p><strong>&nbsp;</strong></p><p>A toxic effect on renal tubules was observed in rats and mice in studies lasting up to 14 days at exposures generally associated with morbidity and mortality. This renal toxicity was also observed in a two-year carcinogenicity study in mice at oral doses of 25, 75 and 150 mg/kg/day. These effects were less severe at lower doses and were characterised by a number of regenerative changes. Exposure at the lowest effective dose was equivalent to 0.6 times the systemic exposure (AUC) in HCV patients (100 mg/day) and 1.2 or 0.8 times the systemic exposure (AUC) in adult or paediatric ITP patients (75 mg/day). After prolonged administration of eltrombopag resulting in systemic exposure (AUC) comparable to that in HCV patients (100 mg/day) or equivalent to 4 to 2 times that in adult or paediatric ITP patients (75 mg/day) no renal toxicity was observed in rats after 28 weeks or in dogs after 52 weeks.</p><p>Due to small safety margins secondary pharmacological effects (e.g. in the cardiovascular system) cannot be ruled out at higher systemic exposure.</p><p><strong>&nbsp;</strong></p><p><em>Carcinogenicity and mutagenicity</em></p><p><em>&nbsp;</em></p><p>Eltrombopag did not prove to be carcinogenic in mice at doses of up to 75 mg/kg/day or in rats at doses of up to 40 mg/kg/day. This is equivalent to 2 times the systemic exposure (AUC) in HCV patients (100 mg/day) and 4 or 2 times the systemic exposure (AUC) in adult or paediatric ITP patients at 75 mg/day. In a bacterial mutation assay and in two in vivo assays in rats eltrombopag was neither mutagenic nor clastogenic at 7 times the systemic exposure (Cmax) in HCV patients (100 mg/day) and 12 to 8 times the systemic exposure (Cmax) in adult or paediatric ITP patients (75 mg/day). In the in vitro mouse lymphoma assay eltrombopag exhibited a slightly positive result (&lt;3-fold increase in mutation frequency). All the in vitro and in vivo findings indicate that eltrombopag does not pose a genotoxic risk to humans.</p><p>&nbsp;</p><p>Newer <em>in vitro </em>studies show a bell-shaped dose-response relationship. Merely doubling the concentration from 6.8 to 13.6 &micro;M eltrombopag resulted in inhibited cell proliferation (cytotoxicity) rather than the expansion of haematopoietic stem cells.</p><p><em>Reproductive toxicity</em></p><p>Eltrombopag did not prove to be teratogenic in rats or rabbits. Eltrombopag had no effect on female fertility, early embryonic development or embryofetal development in rats at doses up to 20 mg/kg/day (equivalent to the systemic exposure (AUC) in HCV patients at 100 mg/day and 2 times the systemic exposure (AUC) in adult or adolescent (12 17 years of age) ITP patients at 75 mg/day). There was no effect on fertility in male rats at doses up to 40 mg/kg/day (equivalent to 2 times the systemic exposure in HCV patients at 100 mg/day). There was also no effect on embryofetal development in rabbits at doses up to 150 mg/kg/day (equivalent to 0.3 times the systemic exposure (AUC) in HCV patients or 0.4 to 0.6 times the systemic exposure (AUC) in adult or paediatric ITP patients at 75 mg/day). However, at maternally toxic doses of 60 mg/kg/day (3 times the systemic exposure (AUC) in HCV patients at 100 mg/day and up to 7 times the systemic exposure (AUC) in adult or adolescent (12 to 17 years of age) ITP patients at 75 mg/day) in rats eltrombopag treatment resulted in embryolethality (increased pre- and post-implantation loss), a lower number of cervical ribs and reduced fetal body weight. In the pre- and postnatal development study in rats (in which the neonates were probably exposed to eltrombopag through their mother&rsquo;s milk) there were no adverse effects on pregnancy, parturition or lactation of F0-generation female rats at maternally non-toxic doses (10 and 30 mg/kg/day) and no effects on the growth, development and neurobehavioural or reproductive function of the offspring.</p><p>&nbsp;</p><p><em>Toxicity studies in juvenile animals </em></p><p>To support the administration of eltrombopag to paediatric patients, studies on juvenile toxicity were performed. The observed higher sensitivity of very young animals was likely due to the higher systemic exposure compared to older juvenile animals. After administration of non-toxic doses to unweaned juvenile rats from day 4 to day 32 (at the end of the administration period approximately equivalent to a 2-year-old child) ocular opacities were observed (pathohistological investigations were not carried out). The administered doses were equivalent to 9 times the maximum systemic exposure in paediatric ITP patients (75 mg/day). However, no cataracts were observed in juvenile rats at doses equivalent to 5 times the systemic exposure (AUC) in paediatric ITP patients. Cataracts were not observed in adult dogs after 52 weeks of treatment with doses equivalent to the systemic exposure (AUC) in HCV patients (100 mg/day) or 2 times the systemic exposure (AUC) in adult or paediatric ITP patients (75 mg/day).</p><p>&nbsp;</p><p>Other information</p><p><strong><em>Effect on diagnostic methods</em></strong></p><p>Eltrombopag is highly coloured and so has the potential to interfere with some laboratory tests. Serum discolouration and interference with total bilirubin and creatinine laboratory tests have been reported. If laboratory test results and clinical findings are inconsistent, evaluation of aminotransferases in the presence of clinical jaundice may help in determining the validity of low total bilirubin levels.</p><p>Blood urea should be determined in the event of unexpectedly high serum creatinine levels. The result should be re-tested using another method as necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Revolade 25&nbsp;mg film-coated tablets</u></p><p><em><u>Tablet core</u></em></p><p>Magnesium stearate</p><p>Mannitol (E421)</p><p>Microcrystalline cellulose</p><p>Povidone</p><p>Sodium starch glycolate</p><p><u>&nbsp;</u></p><p><em><u>Tablet coating</u></em></p><p>Hypromellose (E464)</p><p>Macrogol 400 (E1521)</p><p>Polysorbate 80 (E433)</p><p>Titanium dioxide (E171)</p><p>&nbsp;</p><p><u>Revolade 50&nbsp;mg film-coated tablets</u></p><p><em><u>Tablet core</u></em></p><p>Magnesium stearate</p><p>Mannitol (E421)</p><p>Microcrystalline cellulose</p><p>Povidone</p><p>Sodium starch glycolate</p><p><u>&nbsp;</u></p><p><em><u>Tablet coating</u></em></p><p>Hypromellose (E464)</p><p>Iron oxide red (E172)</p><p>Iron oxide yellow (E172)</p><p>Macrogol 400 (E1521)</p><p>Titanium dioxide (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C/Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Film-coated tablets</u></p><p>Aluminum blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28&nbsp;film-coated tablets and multipacks containing 84 (3&nbsp;packs of 28) film-coated tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Approved by Swissmedic in 12/2023

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>